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Background: Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide with
no curative therapy. A non-canonical Notch ligand, DNER, has been recently identiﬁed in GWAS to associate with
COPD severity, but its function and contribution to COPD is unknown.
Methods: DNER localisation was assessed in lung tissue from healthy and COPD patients, and cigarette smoke
(CS) exposed mice. Microarray analysis was performed on WT and DNER deﬁcient M1 and M2 bone marrow-
derived macrophages (BMDM), and gene set enrichment undertaken. WT and DNER deﬁcient mice were
exposed to CS or ﬁltered air for 3 day and 2 months to assess IFNγ-expressing macrophages and emphysema
development. Notch and NFKB active subunits were quantiﬁed in WT and DNER deﬁcient LPS-treated and un-
treated BMDM.
Findings: Immunoﬂuorescence staining revealed DNER localised to macrophages in lung tissue from COPD pa-
tients andmice. Human andmurinemacrophages showed enhanced DNER expression in response to inﬂamma-
tion. Interestingly, pro-inﬂammatory DNER deﬁcient BMDMs exhibited impaired NICD1/NFKB dependent IFNγ
signalling and reduced nuclear NICD1/NFKB translocation. Furthermore, decreased IFNγ production and
Notch1 activation in recruited macrophages from CS exposed DNER deﬁcient mice were observed, protecting
against emphysema and lung dysfunction.
Interpretation: DNER is a novel protein induced in COPD patients and 6 months CS-exposed mice that regulates
IFNγ secretion via non-canonical Notch in pro-inﬂammatory recruited macrophages. These results provide a
new pathway involved in COPD immunity that could contribute to the discovery of innovative therapeutic tar-
gets.
Funding: This work was supported from the Helmholtz Alliance ‘Aging and Metabolic Programming, AMPro’.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
COPD is currently the third leading cause of death worldwide with
10% of people past forty affected [1,2]. Exposure to environmental par-
ticles, especially cigarette smoke, is the most common cause of COPD.
These patients exhibit a progressive airﬂow obstruction provoked by
small airway ﬁbrosis, alveolar wall destruction (emphysema) and
chronic inﬂammation [3]. In the last decades, it has become evident
that inﬂammatory cells play a key role in initiating and perpetuating
the disease pathology [4–9]. Firstly, inﬂammation is rapidly recogniz-
able by an increase of neutrophils andmacrophages in the lung. Indeed,
macrophage-driven inﬂammation is one of the main triggers driving an
abnormal immune response. It is believed that most of these macro-
phages are derived from bone marrow-derived blood monocytes that
have been quickly recruited to the site of injury rather than expansion
of lung tissue resident macrophages [10]. In a disease context, macro-
phages can acquire distinct phenotypes attending to the local micro-
environmental needs. It is generally accepted the existence of two
main phenotypes: activated (M1) and alternative (M2) macrophages,
EBioMedicine 43 (2019) 562–575
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originally deﬁned based on in vitro settings [11]. M1 are responsive to
type 1-driven inﬂammation by secreting inﬂammatory cytokines like
IL-12a or TNFα, while M2 are induced by type 2 stimulation and are in-
volved in tissue remodelling, anti-inﬂammatory response and
efferocytosis [12]. During COPD, the altered biology of the lung together
with the pleiotropic effects and plasticity of macrophages, results in a
continuous phenotype shifting that makes it difﬁcult to discriminate
M1 and M2 [13]. Indeed, it has been postulated the existence of at
least 8 different phenotypes [10]. However, it is known in COPD that
M1 and M2 subpopulations are defective in their ability to respond to
the environment although it is not clear if there is a dominant pheno-
type [14,15]. Nevertheless, as the disease progresses, dysfunctional
macrophages lead to an exacerbated and inefﬁcient inﬂammatory re-
sponse contributing to tissue damage and enhanced susceptibility to
bacterial and virus infections [14,16]. Macrophage responses are thus
precisely controlled by a wide range of cellular pathways [17], among
them Notch signalling [18], although further investigation is needed to
fully understand the molecular mechanisms.
Given the complexity and heterogeneity of COPD pathology, there is
an unmet therapeutic need since current treatments only alleviate the
symptoms but do not interrupt or reverse disease progression [1]. This
lack of a curative therapy leads to the necessity of searching new targets.
Hancock and colleagues in 2012 identiﬁed a SNP located in the intronic
region ofDNER (Delta Notch like epidermal growth factor related recep-
tor), as themost signiﬁcant SNP associated with the FEV1/FVC ratio and
FEV1 [19]. Indeed, a further GWAS using an expanded cohort (16,707
subjects) conﬁrmed the relevance of this SNP as a genetic risk for
COPD and pulmonary function [20].
DNER is a transmembrane protein that belongs to the non-canonical
Notch ligand family and binds to the Notch1 receptor [21,22]. In con-
trast to canonical, the non-canonical pathway is triggered by a different
family of ligands that differ in their protein structure and whose down-
stream cascade leads to CSL (CBF1, Suppressor of Hairless, Lag-1) inde-
pendent Notch activation. DNER was ﬁrst described to be highly
expressed by Purkinje neurons where it played a key role in cerebellum
development [23,24], but it is also involved in differentiation and
proliferation during cancer and stemness [25,26]. Nevertheless, its
function in other cell types or in lung disease is completely unknown.
Moreover, implication of the non-canonical Notch pathway in the
immunopathogenesis of COPD has never been elucidated. Therefore,
we hypothesize that the non-canonical Notch ligand DNER contributes
to the promotion of pro-inﬂammatory responses during the progression
of COPD pathogenesis.
Here, we demonstrate that DNER is expressed and localised to mac-
rophages of experimental and human COPD. Furthermore, we provided
evidence ex vivo and during disease pathogenesis that downstream
DNER signalling is crucially involved in IFNγ secretion by pro-
inﬂammatory murine macrophages via activation of Notch1-NFκB
crosstalk. Collectively, this study is the ﬁrst to describe the function
and mechanism of DNER in macrophages in the context of chronic
lung inﬂammation and opens new avenues to discover novel therapeu-
tic targets for COPD patients.
2. Material and methods
2.1. Human tissue samples
Lung core samples from COPD patients (Supplementary Table 1)
prior to lung transplantation were provided by Dr. Stijn Verleden (Uni-
versity of Leuven, Belgium), following ethical approval of the University
of Leuven Institutional Review Board (S52174). All participants gave
written consent and experiments were carried out following the princi-
ples described in the Declaration of Helsinki. COPD patients were
explanted between 2009 and 2015. Controls were obtained from
lungs not suitable for transplantation due to different reasons (kidney
tumor, logistics, presence of microthrombi). Lung conditionswere eval-
uated based on stereology/morphology parameters and CT. According
to Belgian law, declined donor lungs can be designated for research
after second opinion examination. Control subjects were explanted be-
tween 2011 and 2018. After organ removal, lungs were air-inﬂated at
10 cm H2O pressure and ﬁxed with liquid nitrogen vapour. Lungs
were then cut into pieces with a band saw and sampled with a core
bore. For parafﬁn embedding, lung pieces were sliced and ﬁxed in 4%
paraformaldehyde. For isolation of total RNA (peqGOLD Total RNA Kit,
Peqlab), lung cores were snap frozen in liquid nitrogen.
2.2. Human monocyte derived macrophages
Human macrophages were differentiated from PBMCs of four
healthy donors. Informed written consent was provided by all
Research in context
Evidence before this study
COPD is a complex and progressive disease whose pathology is
mainly driven and perpetuated by chronic inflammation. In fact,
current treatments are mainly immunosuppressive drugs in combi-
nationwith bronchodilators thatmitigate the symptoms but do not
cease disease progression. Hence, there is an urgent need of find-
ing new molecular targets that can be implicated in disease devel-
opment. Therefore, we searched for recent GWAS studies with
healthy and COPD patients using PubMed and the GWAS central
database (search terms: “GWAS COPD” “SNP COPD”). We found
DNER as a potential genetic risk confirmed by 2 independent
GWAS. Additionally, DNER gene expression was upregulated in
smoker patients analysed in the GWAS studies. However, we
could not find any study addressing DNER lung cell localisation
and function (sources: Pubmed, UniProt, NextBio). Thus, our aim
was to unravel how DNER is implicated in COPD development.
Added value of this study
Here we showed that DNER is expressed in pro-inflammatory re-
cruited alveolar macrophages where it regulates IFNγ release dur-
ing chronic inflammation in a CS-induced COPD mouse model.
Furthermore,weprovided the first evidence ofDNER as a regulator
of Notch1-NFKB crosstalk in activated macrophages.
Implications of all the available evidence
Today there are few studies dedicated to following up new gene
candidates obtained from GWAS, usually due to the considerable
lack of knowledge about these novel proteins. DNER is a protein
well described in the nervous system but no detailed research
has been investigated in other organs or cell types. This is the
first study showing a functional role and molecular mechanism
for DNER in lungmacrophages, regulating IFNγ release.Moreover,
the controversial and little understanding of the non-canonical
Notch pathway entails an additional novel angle to our research,
since the molecular mechanism of DNER published in neurons
was not observed in macrophages. Lastly, it is known that ciga-
rette smoke IFNγ-driven inflammation is the main trigger of
COPD immunopathology, mostly released by macrophages and
Th1 cells. Here we showed that DNER regulates IFNγ expression
in macrophages during CS-induced chronic inflammation. Taken
altogether, our study offers new molecular and functional knowl-
edge on DNER and non-canonical Notch signalling as well as con-
tributes to enlightening novel therapeutic strategies for COPD
patients.
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participants and the local ethical review board approved the use of
human tissue (180–14 LMU board). Brieﬂy, 5 × 106 PBMCs were cul-
tured in amino acids, 1 mM sodium pyruvic acid, 9 mg of bovine insulin
(Sigma Chemical Co., St Louis,Mo) and the presence of 100 ng/mlM-CSF
for 7 days. After differentiation,macrophageswere treated for 24 hwith
1 μg/ml LPS (E. coli O55:B5, Sigma-Aldrich) and 5% cigarette smoke ex-
tract (CSE).
2.3. Mice
C57BL/6 N Dnertm3b(EUCOMM)Hmgu (Dner−/−) mice were obtained
from the German Mouse Clinic (GMC), Helmholtz Zentrum München.
Mice were allowed food and water ad libitum, kept at a constant tem-
perature and humidity, with a 12-h light cycle, under speciﬁc pathogen
free conditions. All animal experimentswere performed following strict
governmental and international guidelines and were approved by the
local government for the administrative region of Upper Bavaria,
Germany.
2.4. Cigarette smoke exposure
8–12weeks old C57BL/6 N and Dner−/−micewere exposed to 100%
mainstream of 500 mg/m3 cigarette smoke (CS) [57], using 3R4F re-
search cigarettes (Filter removed, TobaccoResearch Institute, University
of Kentucky), for 50 min twice/day, for 3 days, and 5 days/week for
2 months or 6 months. Mice exposed to ﬁltered air were used as
controls.
2.5. Lung function test
Lung function analysis was performed as previously described [4]. In
summary, anaesthetised mice were tracheostomized and cannulated
before the test. Respiratory function (forced expiratory volume after
100ms, FEV100)was analysed using a forced pulmonarymaneuver sys-
tem [5] (Buxco Research Company, Data Sciences International) run-
ning FinePointe Software (version 6, Data Sciences International) and
the quasistatic PV maneuver protocol.
2.6. Bronchoalveolar lavage (BAL)
Lungswerewashed three timeswith 500 µl of sterile PBS (Gibco, Life
Technologies) supplementedwith Complete Protease Inhibitor Cocktail
tablets (Roche Diagnostics). BAL cells were pelleted and resuspended in
500 µl RPMI-1640 medium (Gibco, Life Technologies) for the total cell
count. Cytospins of the cell suspensions were prepared and stored at
−80 °C for immunoﬂuorescence staining.
2.7. Mouse lung processing
The two right lower lung lobes were stored in liquid nitrogen for
RNA and protein isolation. The right upper two lobes were dissociated
into single cell suspensions in MACS buffer using the lung dissociation
kit and gentleMACS Dissociator (Miltenyi Biotec) for ﬂow cytometry
analysis. The left lung was ﬁxed with 6% paraformaldehyde under a
pressure of 20 cm inﬂation and parafﬁn embedded.
2.8. Flow cytometry
106 cells from ﬁltered single cell lung homogenates or BAL cell pel-
lets were blocked with puriﬁed anti-mouse CD16/CD32 (Clone: 93,
eBioscience) for 20 min followed by 30 min incubation with antibody
cocktails on ice. For intracellular staining, cells were ﬁxed with 4% PFA
for 10 min and then permeabilized with 1% BSA/0.5% Saponin/PBS
buffer followed by 10 min incubation with anti-mouse CD16/CD32
and a second incubation of antibody cocktails in the permeabilization
buffer. After washing and re-suspending in MACS buffer (Miltenyi
Biotec), cells were analysed on a BD FACSCanto II ﬂow cytometer
(BD Biosciences) running BD FACSDiva software. B cell and T cell
staining was performed with: APC-conjugated anti-CD19 (clone: 6D5,
Miltenyi Biotec), APC-Vio770-conjugated anti-CD3e (clone: 17A2,
Miltenyi Biotec), PE-Vio770-conjugated anti-CD22 (clone: Cy34.1,
Miltenyi Biotec), PE-conjugated anti-CD80 (clone: 16-10A1, Miltenyi
Biotec), PerCP-Vio700-conjugated anti-MHCII (clone: M5/114.15.2,
Miltenyi Biotec), VioGreen-conjugated anti-CD69 (clone: H1.2F3,
Miltenyi Biotec), FITC-conjugated anti-IgG (Biolegend). For the macro-
phage proﬁle: VioGreen-conjugated anti-CD45 (clone: 30F11, Miltenyi
Biotec), APC-Vio770-conjugated anti-Ly6C (clone: 1G7.G10, Miltenyi
Biotec), VioBlue-conjugated anti-Ly6G (clone: 1A8, Miltenyi Biotec),
FITC-conjugated anti-MHCII (clone: M5/114.15.2, Miltenyi Biotec),
PerCP-Vio700-conjugated anti-F4/80 (clone: REA126, Miltenyi Biotec),
PE-Vio770 conjugated anti-Siglec-F (clone: ES22-10D8, Milteyi
Biotec), PE-conjugated anti-CD11b (clone: M1/70.15.11.5, Miltenyi
Biotec), APC-conjugated anti-CD11c (clone: N418, Miltenyi Biotec).
For intracellular staining: APC conjugated anti-IL-4 (clone: 11B11,
BIOZOL Diagnostica) and FITC conjugated anti-IFNγ (clone: XMG1.2,
Life Technologies).
2.9. Immunoﬂuorescence
3 μmmurine or human lung tissue sections were deparafﬁnized and
rehydrated followed by heat-induced epitope retrieval using HIER Cit-
rate Buffer (pH 6.0, Zytomed Systems). For the cytospins, cells were
ﬁxed by incubation with methanol for 10 min followed by 1 min of ac-
etone. Sections or cytospinswere blockedwith 5% BSA for 30min, incu-
bated overnight at 4 °C with primary antibodies and 1 h at room
temperature with secondary antibodies (anti-goat Alexa Fluor 568,
anti-rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 488 and anti-
rabbit Alexa Fluor 555, Life Technologies) diluted in 1% BSA. Images at
different magniﬁcations were captured using Axio Imager with an M2
microscope (Zeiss) and processed with ImageJ 1.x [58]. Primary anti-
bodies common for human and murine tissue: Galectin-3 (1:50 sc-
32790, Santa Cruz), CD31 (1:50 ab28364, Abcam), ACTA-2 (1:600
ab5694, Abcam), Pro-SPC (1:100 AB3786, Chemicon International).
Human tissue: DNER (1:100 AF3646, R&D Systems), CC10 (1:100 sc-
365992), NOS2 (1:20 sc-8310). Murine tissue: DNER (1:50 AF2254,
R&D Systems), NICD1 (1:25 ab8925, Abcam).
2.10. Quantitative morphometry
Design-based stereology was used to analyse mean chord length in
H&E stained tissue sections using the newComputer Assisted Stereolog-
ical Toolbox (newCAST, Visiopharm) and anOlympus BX51 lightmicro-
scope as described [5]. In brief, 20 frameswere randomly selected by the
software across multiple sections under the x20 objective and
superimposed by a line grid and points. The intercepts of lines with al-
veolar wall (Isepta) and points localised on air space (Pair) were counted
and calculated as MCL =∑Pair x L(p) /∑Isepta x 0.5, where L(p) is the
line length per point.
2.11. Professional APC isolation and stimulation
Bone marrow was ﬂushed from femurs and tibias of C57BL/6 N and
Dner−/− mice with RPMI-1640 medium. Bone marrow cells were
passed through 40 μm ﬁlters (Miltenyi Biotec), counted and resus-
pended in 5% fetal bovine serum, 50 μM β-mercaptoethanol and
100 U/ml penicillin and streptomycin RPMI-1640 medium. 2 × 106
cells/ml were plated in T25 Flasks for protein isolation and nuclear ex-
tractions or in 24well plates for RNA isolation.Mediumwas additionally
supplementedwith 20 ng/ml ofmurine recombinantM-CSF to generate
bone marrow derived macrophages (BMDM) or 20 ng/ml murine re-
combinant GM-CSF for bone marrow derived dendritic cells (BMDC).
Medium was changed every 2–3 days carefully discarding non-
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adherent cells. For BMDM, on day 7 fresh medium without M-CSF was
added and left overnight. For BMDCs, on day 7 to 8 adherent cells
were harvested and 1 × 107 cells were seeded in 100 mm petri dishes
to keep them in culture for an additional 24-48 h. Thenon-adherentma-
turing DCs were collected as they were released. BMDM were stimu-
lated with 1 μg/ml LPS (from E.coli 0111:B4, Sigma-Aldrich) and
20 ng/ml of recombinant murine IFNγ (M1 phenotype) or with
20 ng/ml of recombinant murine IL-4 (M2 phenotype) for 24 h.
BMDCs were treated with 1 μg/ml LPS for 24 h. All cytokines were pur-
chased from ImmunoTools.
2.12. Th differentiation
Naive CD4 T cells were puriﬁed from total murine splenocytes using
the CD4+ CD62L+ T cell Isolation Kit II (Miltenyi Biotec) and cultured at
1.5 × 106/ml in RPMI1640medium supplementedwith 10%FCS, 0.1mM
beta-mercaptoethanol, 100 U/ml penicillin Streptomycin, 10 mM
HEPES, 1 mM Sodium Pyruvate, 0.1 mM non essential amino acids and
1 × MEM Vitamin Solution. These were then stimulated for 48 h with
anti-CD3/anti-CD28 coupled beads, along with recombinant human
TGFβ (10 ng/ml, R&D Systems, Wiesbaden, Germany), IL-6 (60 ng/ml,
R&D Systems), anti-IL-4 (10 μg/ml, BioLegend, San Diego, CA), anti-IL-
12 (10 μg/ml, BioLegend), anti-IFNγ (5 μg/ml, BioLegend) and anti-IL-
2 (2.5 μg/ml, Miltenyi Biotec) for Th17 differentiation. For Th2, anti-
CD3/anti-CD28 coupled beads were supplemented with recombinant
mouse IL-4 (20 ng/ml, R&D systems, anti-IL12 (10 μg/ml) and anti-
IFNgamma (5 μg/ml) for 96 h. For Th1, with recombinant IL-12p70
(10 ng/ml, BD Pharmingen) and anti-IL-4 (10 μg/ml) for 96 h. For Treg
differentiation anti-CD3/anti-CD28 coupled beads were supplemented
with recombinant human TGFβ (10 ng/ml, R&D Systems) and
1000 IE/ml recombinant human IL-2 (ProleukinS, Novartis) for 72 h.
Th0 control cells were stimulated with anti-CD3/anti-CD28 coupled
beads alone for a comparable period of time. For Th1 and Th2 differen-
tiation and their Th0 control, the culture volumewas doubled withme-
dium containing 1000 IE/ml recombinant human IL-2 at 40 h and at 80h
the medium was replaced with medium lacking IL-2.
2.13. Cell lysates
To obtain whole cell lysates, BMDMwere washed with ice-cold PBS
and collected by scraping into RIPA buffer. Samples were incubated for
30 min on ice mixing every 5 min. Lysates were centrifuged at
13000 rpm for 15min at 4 °C and supernatants retained. To perform cy-
toplasmic and nuclear extractions from BMDM, a commercial kit was
used and undertaken as per manufacturers instructions (Nuclear Ex-
tract Kit 40010 and 40410, Active Motif).
2.14. Western blotting
20 μg of cell lysates were diluted in Laemmli Buffer (BioRad) con-
taining β-mercaptoethanol (Gibco, Life Technologies) and incubated
for 10 min at 95 °C. Protein samples were separated on a 10% sodium
dodecyl sulfate–polyacrylamide gel by electrophoresis and wet-
transferred to a PVDF membrane (BioRad). Membranes were blocked
with Roti buffer (Roti®-Block protein free, Roth) for 1 h, then incubated
with primary antibody overnight at 4 °C followed by 1 h incubationwith
secondary antibody at room temperature. Primary antibodies: NICD1
(1:500, ab8925, Abcam), RelB (1:200, sc-226, Santa Cruz), cRel (1:100,
sc-6955, Santa Cruz), p105/50 (1:100, sc-1190, Santa Cruz), p65
(1:500, sc-372, Santa Cruz), pIKKα/β (1:1000 #2697, Cell Signalling),
IKKα (1:1000 #2682S, Cell Signalling), IKKβ (1:1000 clone D30C6,
#8943, Cell Signalling). Secondary antibodies: rabbit anti-goat IgG-
HRP (1:5000, 2768 Santa cruz), Anti-rabbit IgG-HRP (1:3000, 7074P2
New England Biolabs), and anti-mouse (1:3000, NA931V GE
Healthcare).
2.15. Cigarette smoke extract (CSE) preparation
CSE was prepared as previously described [4]. Brieﬂy, cigarette
smoke from 3 cigarettes (3R4F, Tobacco Research Institute, University
of Kentucky) was bubbled through 30 ml of cell culture medium at a
constant speed, in a closed environment. The resultant solution was
considered as 100% CSE.
2.16. ELISA
Total IFNγ cytokine levels were measured in BAL from 3 days and
2 months CS exposed C57BL/6 N and Dner−/− mice and in cell
supernantants from BMDMs using a commercial kit following theman-
ufacturer's instructions (murine IFNγ PEP-900-K98, Preprotech).
2.17. RNA isolation and quantitative real time RT-PCR and end point PCR
RNA from tissue or cells was isolated as described using the
peqGOLD total RNA kit (Peqlab). 0.5-1 μg RNA was reverse transcribed
using Random Hexamers and MuLV Reverse Transcriptase (Applied
Biosystems). To analyse gene expression, Platinum™ SYBR™ Green
qPCR SuperMix-UDG (Thermo Fisher) on a StepOnePlus 96 well Real-
Time PCR System (Applied Biosystems) was used. Primer sequences
can be found in Supplementary Table 2. Gene relative expression was
calculated using HPRT1 or Hprt1 as housekeeping genes (2-∆Ct). For
end point PCR, cDNA fragments were ampliﬁed in a thermo cycler
using Green GoTaq Polymerase (Promega) and separated in a 2% aga-
rose gel. Primer sequence: Dner 5′-CAT AAT CCT GCC CCG CTC TC-3′,
3′-TCATTTGAGTGGCTGTCCCC-5′.
2.18. Microarray
Total RNA from C57BL/6 N and Dner−/−M0,M1 andM2 BMDMwas
isolated with peqGOLD total RNA kit (Peqlab) including digestion of re-
maining genomic DNA. The Agilent 2100 Bioanalyzerwas used to assess
RNA quality and only high quality RNA (RIN N 7) was used for microar-
ray analysis. For the expression proﬁling, about 30ng of RNAwas ampli-
ﬁed using the Ovation Pico WTA System V2 in combination with the
Encore Biotin Module (NuGEN Technologies, Inc., San Carlos, CA, USA).
Ampliﬁed cDNA was hybridized on a mouse Gene 2.0 ST array
(Affymetrix, Santa Clara, CA, USA). Staining and scanning (Scanner
3000 7G) was done according to the Affymetrix expression protocol in-
cludingminormodiﬁcations as suggested in the Encore Biotion protocol
(NuGEN Technologies, Inc). Array data has been submitted to GEO
(GSE119257).
2.19. Transcriptome analysis
Expression console (v.1.4.1.46, Thermo Fisher Scientiﬁc Inc.) was
used for quality control and to obtain annotated normalized RMA
gene-level data (standard settings including median polish and
sketch-quantile normalisation). Statistical analyses were performed by
utilizing the statistical programming environment R (R Development
Core Team [59]). Genewise testing for differential expression was
done employing the (limma) t-test (p b 0.05) and cut-offs for ratio
(N1.3-fold) and expression levels (average N 16 in at least one experi-
mental group per comparison) were applied. PCA was done in R and
the upstream regulator analysis was generated through the use of
QIAGEN's Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity).
2.20. Gene set enrichment analysis (GSEA)
Enrichment of deﬁned sets of genes in our microarray data and data
obtained from series matrix ﬁles downloaded from the NCBI GEO data-
base (GSE8608) was performed using the GSEA software from the
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Broad Institute (http://www.gsea-msigdb.org/gsea/index.jsp) [60]. The
followingmolecular signature databases obtained from theGSEA collec-
tion were examined; canonical pathways (CP) REACTOME (gene set
sizeﬁlters: 30–500genes, 270 gene sets), geneontology (GO)molecular
function (gene set ﬁlters: 15–500 genes, 659 gene sets).
2.21. Statistical analysis
No statistical procedure was applied to deﬁne the number of sam-
ples. GraphPad Prism (Version 6, GraphPad Software) was used for all
statistical analysis. Data are presented as mean ± SD with sample size
and number of repeats indicated in the Figure legends. For comparison
between two groups statistical signiﬁcancewas analysedwith Student's
t-test p values b.05 were considered signiﬁcant. For multiple compari-
sons, one-way ANOVA (one variable) or two-ways ANOVA (two
variables) and Tukey's multiple comparisons test were used (*P b 0.05,
**P b 0.01, ***P b 0.001, ****P b 0.0001).
3. Results
3.1. DNER is localised to activated macrophages in COPD patients
To determine the relevance of DNER in COPD evidenced by the
GWAS studies [19,20], we assessed DNER expression in whole lung ho-
mogenates from healthy and COPD patients. DNER transcription was
signiﬁcantly increased in COPD patients compared to healthy controls
independently of both gender and age (Fig. 1a, Supplemental Fig. 1a-
b). In human lung histological sections, DNER co-localised with the
macrophage marker Galectin-3 in both healthy and COPD patients
(Fig. 1b, Supplemental Fig. 1c), suggesting that macrophages are the
predominant DNER-expressing cells. Given the predominance of in-
ﬂammation in a COPD lung, human monocyte derived macrophages
(MDM) were treated with LPS plus cigarette smoke extract (CSE) to
mimic the COPDmicroenvironment in vitro. Interestingly,DNER expres-
sion was signiﬁcantly induced as well as the pro-inﬂammatory marker,
TNF (Fig. 1c). Supporting this data, DNER co-localised with the pro
inﬂammatoryM1markerNOS2 inhuman lung tissue (Fig. 1d). These re-
sults strongly suggest that pro-inﬂammatory human macrophages are
the main cell type expressing DNER in the human lung and likely har-
bour DNER function during COPD development.
3.2. DNER is expressed in murine M1 macrophages and regulates IFNγ
signalling
The cigarette smoke (CS)-induced COPD mouse model was used to
further investigate the role of DNER in the immunopathogenesis of
COPD. After 6months of CS exposure, wild-type (WT)micedevelop em-
physema, airway remodelling and chronic lung inﬂammation [4], the
main characteristic pathological changes observed in human COPD pa-
tients [3,27]. Immunoﬂuorescence staining revealed that DNER local-
ised to macrophages of CS-exposed COPD mice (Fig. 2a), supporting
the previous ﬁndings in human tissue. As already mentioned,
macrophage-driven inﬂammation in the context of COPD plays an im-
portant role in disease onset. Therefore, we next exposed bonemarrow
derivedmacrophages (BMDM) fromWTmice to pro (M1) or anti- (M2)
inﬂammatory stimuli and assessed Dner expression. Validation of
BMDMdifferentiationwas conﬁrmed by FACS analysis (90.7% of the ob-
tained population was F4/80+ CD11b+ CD11c− Ly6g− Ly6c−, Supple-
mentary Fig. 1d). Interestingly, M1 BMDM revealed signiﬁcantly
increased expression ofDner (Fig. 2b). In contrast, bonemarrowderived
DCs (BMDC) treated with LPS did not increase Dner levels, suggesting
that murine macrophages are the only antigen presenting-cell that ex-
press Dner in response to inﬂammation (Supplementary Fig. 1e). To ad-
dress whether DNER has a role in macrophage polarisation, microarray
analysis of WT and DNER deﬁcient BMDM polarised populations was
performed. DNER deﬁcient mice were created by deletion of Dner
exon 3 using the Cre-LoxP system and knock out efﬁciency was con-
ﬁrmed by the absence of DNER transcript and protein in brain tissue
and macrophage lysates from knock out mice (Supplementary Fig. 2a-
c). Principal component analysis (PCA) revealed that M0, M1 and M2
populations were similarly clustered for both WT and DNER deﬁcient
BMDM, indicating that global macrophage polarisation is not affected
by the absence of DNER (Supplementary Fig. 2d). Likewise, M1 (Tnf,
il12a) and M2 (Fizz1, Arg1) markers exhibited comparable expression
levels in both genotypes, conﬁrming similar polarisation (Supplemen-
tary Fig. 2e).
Even though DNER did not inﬂuence macrophage polarisation, its
expression levels are signiﬁcantly elevated in M1 macrophages
(Fig. 2b), which could suggest a role in signalling pathway regulation.
To further analyse the downstream cascade of DNER in M1 macro-
phages, we performed gene set enrichment analysis (GSEA). Investigat-
ing a combination of 270 REACTOME pathway gene sets, revealed that
interferon signalling was the most enriched pathway in WT M1 com-
pared to DNER deﬁcient M1 BMDM (Fig. 2c, d). Given the diversity
and complexity of interferon signalling, we next determined which
type of interferon pathway is impaired in DNER deﬁcientmice. Interest-
ingly, induction of type II interferon (Ifng), but not type I (Ifnb1), was
signiﬁcantly abrogated in M1 polarised DNER deﬁcient compared to
WT BMDM (Fig. 2e). Supporting the idea of Ifng as a possible down-
stream target of DNER, IFNγ signalling was found to be enriched in
WTM1 (Fig. 2f, Supplementary Fig. 2f). Furthermore, GSEA from an on-
line available dataset of monocyte derived macrophages (MDM) ob-
tained from healthy and COPD patients (GSE8608) [28], revealed an
enriched IFNγ pathway in COPDMDM (Fig. 2g). It should be considered
that T cells, speciﬁcally Th1 cells, serve as a major source of IFNγ. How-
ever, in vitro differentiated WT T cell subpopulations showed very low
expression of Dner, therefore making it unlikely that DNER regulates
IFNγ in T cells (Supplementary Fig. 3f). Hence, these data indicated
that DNER is signiﬁcantly enhanced inM1macrophageswhere it specif-
ically regulates IFNγ expression.
3.3. DNER regulates IFNγ in recruited macrophages during chronic CS
exposure
The persistent inﬂammation observed in COPD is mainly caused by
the continuous secretion of pro-inﬂammatory cytokines, among them
IFNγ is essential to maintain cytokine production and immune cell re-
cruitment and polarisation [29]. To investigate whether in vivo DNER
deﬁciency affects the release of IFNγ during acute and chronic inﬂam-
mation, WT and DNER deﬁcient mice were exposed to CS for 3 days
(acute) or 2 months (chronic) (Supplementary Fig. 3a). Immunoﬂuo-
rescence staining of the bronchoalveolar lavage (BAL) macrophages
from 3 days and 2 months of CS exposure revealed increased DNER ex-
pression in macrophages compared to ﬁltered air treated animals
(Fig. 3a), conﬁrming that DNER expression is triggered in pro-
inﬂammatory macrophages (M1). Similarly, in BAL ﬂuid from 2 month
CS-exposed mice, IFNγ levels were signiﬁcantly induced in WT mice
but this was not signiﬁcantly enhanced in DNER deﬁcient animals
(Fig. 3b). To clarifywhether DNER regulatesmacrophage IFNγ secretion
during chronic inﬂammation, we analysed the lung macrophage popu-
lation from chronic CS-exposedmice byﬂow cytometry. In linewith the
in vitro results, CD45+ Ly6g− F4/80+ alveolar macrophages from WT
mice exhibited signiﬁcant IFNγ induction after chronic CS exposure
which was diminished in DNER deﬁcient mice (Fig. 3c).
To elucidate whether recruited or resident macrophages differen-
tially secrete IFNγ in the absence of DNER, we analysed both popula-
tions by gating on CD45+Ly6g− F4/80+ SiglecF− (recruited) or
CD45+Ly6g− F4/80+SiglecF+ (resident) populations (Fig. 3d). Strik-
ingly, recruited macrophages from DNER deﬁcient mice were unable
to secrete IFNγ in response to CS exposure, as determined by both the
percentage of IFNγ positive cells and the mean ﬂuorescence intensity
(MFI) (Fig. 3e). In contrast, resident macrophages did not show any
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Fig. 1.DNER is signiﬁcantly upregulated in lung tissue fromCOPDpatients and localised to pro-inﬂammatorymacrophages. (a)DNERmRNAabundance in lung tissue fromhealthy subjects
(n=10) and COPD patients (n=15). **p-value= 0.003, unpaired t-test. Data shownmean values± SD. (b) Representative immmunoﬂuorescence images from healthy and COPD lung
tissue (n= 2/3) stained to detect localisation of DNER (red), DAPI (blue) and Pro-SPC/CC10/CD31/Acta2/Galectin-3 (green). Scale bar, 10 μm. (c) DNER and TNFmRNA abundance in
human monocyte derived macrophages obtained from PBMCs of healthy subjects (n= 4) and treated with 1 μg/ml LPS in combination with cigarette smoke extract (CSE) 5% for 24 h.
Paired t-test, *p= 0.0408. (d) Representative immunoﬂuorescence pictures of DAPI (blue), NOS2 (green) and DNER (red) staining in healthy and COPD lung tissue (n= 3). Scale bar,
10 μm.
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Fig. 2.DNER is localised tomacrophages in 6m CS-exposedmice and regulates IFNγ response inM1 BMDM. (a) Representative immmunoﬂuorescence images of lung tissue from ﬁltered
air (FA) and 6 month CS-exposed mice stained with DNER (Red), DAPI (Blue) and Galectin-3/Pro-SPC/Acta-2/CD31 (green) (n= 2–3 mice per group). Scale bar, 10 μm. (b) DnermRNA
levels in WT and DNER deﬁcient bone marrow derived macrophages (BMDM) treated with 1 μg/ml LPS and 20 ng/ml IFNγ (M1) or 20 ng/ml IL-4 (M2) or untreated (M0). (c) Top 5
pathways with the highest Normalized Enriched Scores (NES) in Gene set enrichment analysis (GSEA) of the microarray data fromWT M1 vs DNER deﬁcient M1 BMDM using a list of
270 REACTOME pathway gene sets obtained from the Broad Institute software. (d) Enrichment plots from (2c) of WT M1 vs DNER deﬁcient M1 BMDM. (e) mRNA levels of Ifnb1 and
Ifng in M0 and M1 BMDM populations. (f) Enrichment plot of IFNγ signalling following GSEA analysis of the microarray data from WT M1 vs DNER deﬁcient M1 BMDM.
(g) Enrichment plot of IFNγ signalling from the GSEA analysis of Monocyte Derived Macrophages (MDM) obtained from healthy and COPD patient microarray data (NCBI GEO dataset,
GSE8608). Two-way ANOVA, Tukey's multiple comparisons test, ****P b 0.0001 (b, e). Representative 2 independent experiments out of 5, n= 3mice, 2–3 replicates per mouse (b, e).
One experiment, n= 3 (c-d, f-g). Data shown mean values ± SD.
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difference in IFNγ secretion between both genotypes after CS exposure
(Fig. 3f). Along similar lines, innate and adaptive immune populations
after CS exposure were not altered in the lungs of DNER deﬁcient mice
compared toWT (Supplementary Fig. 3d, e). Thus, explaining the partial
enhancement of total IFNγ levels in BAL from 2 month CS-exposed
DNER deﬁcient mice (Fig. 3b). Previous studies have shown that high
levels of IFNγ leads to signiﬁcant emphysema development [30]. Inter-
estingly, 2 months CS exposed DNER deﬁcient mice showed a signiﬁ-
cantly retained lung function, measured as FEV100, compared to CS
exposed WTmice (Supplementary Fig. 3b). This was further supported
by an absence of emphysema development in DNER deﬁcientmice after
2 months CS exposure (Supplementary Fig. 3c). Taken together, these
results revealed that DNER regulates IFNγ secretion in lung recruited
macrophages and is crucial for CS-induced emphysema development.
3.4. DNER activates Notch1 signalling in response to CS
Several studies have shown that Notch-NFκB crosstalk signalling
regulates IFNγ transcription [31,32]. To determine whether DNER deﬁ-
ciency affects Notch signalling in lung macrophages, we quantiﬁed the
number of nuclear NICD1+ Gal3+ cells (white arrows, Fig. 4a) in lung
sections from FA and 2 months CS-exposed mice. Interestingly, DNER
deﬁcient mice revealed signiﬁcantly reduced nuclear translocation of
NICD1 in macrophages after 2 months of CS exposure in comparison
to WT mice (Fig. 4a-b). In support, the Notch1 signalling pathway was
enriched in WT M1 compared to DNER deﬁcient M1 macrophages
(Fig. 4c, Supplementary Fig. 4a) and a similar pattern was observed in
MDM from COPD patients (Fig. 4d). This could suggest that COPD mac-
rophages have an altered Notch signature similar to the one observed in
WT versus DNER deﬁcient lung macrophages after CS exposure. Taken
altogether, this data demonstrated that CS inducedNotch1 activity in al-
veolar macrophages in vivo via DNER.
Further, to decipher whether DNER regulates IFNγ expression via
Notch1-NFκB crosstalk, WT and DNER deﬁcient BMDM were treated
with LPS ex-vivo. First, we evaluated our previous results (Fig. 2e,
f) by measuring IFNγ cytokine levels in the cell supernatants. As ex-
pected, IFNγ concentration after LPS stimulation was signiﬁcantly re-
duced in the DNER deﬁcient BMDM cell medium compared to the WT
BMDM (Supplementary Fig. 4b). Upon LPS stimulation, DNER deﬁcient
BMDM showed reduced release of NICD1 to the cytoplasm and com-
plete absence of NICD1 nuclear translocation in contrast to WT BMDM
(Fig. 5a). Notch1 expression was similarly increased after LPS treatment
in both genotypes suggesting that reduced NICD1 in DNER deﬁcient
BMDM is not due to lower Notch1 receptor levels (Fig. 5b). Likewise,
the gene expression of other Notch family members expressed in mac-
rophages was not affected in the DNER deﬁcient BMDM (Fig. 5b).
Consistent with this, we found that the quantiﬁcation of NFκB sub-
units revealed that cytoplasmic levels of c-Rel, p105 and p50 were re-
duced in DNER deﬁcient BMDM compared to WT before and after LPS
treatment (Fig. 5c). Interestingly, there was no nuclear translocation
of the NFκB subunits in DNER deﬁcient BMDM with the exception of
RelB, whose levels were reduced, compared to WT BMDM (Fig. 5c).
This pronounced inhibition of the NFκB pathway was independent of
IKKα/β activity, as its phosphorylation levels were unaltered (Fig. 5d).
Together, this data clearly indicated that DNER is necessary for Notch
activation and essential for nuclear activation of NFkB signalling after
LPS treatment of pro-inﬂammatory macrophages. Transcriptomic
analysis by GSEA and upstream regulator prediction using Ingenuity
Pathway Analysis (IPA) supported this data. GSEA revealed enrichment
of theNFκB downstream cascade inWTM1 compared to DNER deﬁcient
M1 BMDM (Fig. 5e and Supplementary Fig. 4c) and IPA predicted, with
the lowest negative Z-score, the NFκB complex to be themost inhibited
upstream regulator in DNER deﬁcient M1 BMDM (Supplementary
Fig. 4d). Taken all together, we have demonstrated that DNER is activat-
ing the Notch1-NFκB crosstalk pathway in BMDM after LPS activation.
4. Discussion
The absence of a curative therapy for COPD, make necessary the ex-
ploration of new targets. This is the ﬁrst study that investigates the role
of DNER, a novel non-canonical Notch ligand that appeared to be signif-
icantly associated with COPD patients in recent GWAS studies [19].
Here, we showed that DNER is upregulated in COPD human lung
homogenates and localised to pro-inﬂammatory human and murine
macrophages. In a CS-induced COPD mouse model, induced DNER ex-
pression is necessary for IFNγ production in lung recruited macro-
phages during chronic inﬂammation. This was further supported
in vitro, where M1 polarised DNER deﬁcient BMDM failed to induce
Ifng transcription in response to pro-inﬂammatory stimulus due to an
aberrant activation of Notch1-NFκB crosstalk.
In sections of COPD and healthy lung tissue, we observed that DNER
is predominantly expressed by NOS2 positive macrophages and that its
mRNA levels are induced in human primary macrophages after an in-
ﬂammatory stimulus. This might lead to the debate of whether DNER
upregulation is related to COPD or is a smoking effect. Nevertheless,
the authors from the GWAS also presented evidence of a lack of associ-
ation between DNER and distinct smoking phenotypes, concluding that
the SNP is associated with declined lung function rather than smoking.
These ﬁndings together with our results, suggest that the presence of
the SNP entails susceptibility for DNER expression in COPD patients. In-
deed, exploration of the SNP genomic region using the ENSEMBL data-
base showed that the SNP is located in a methylation-sensitive histone
site and 286 bp upstream to transcription factor binding motifs (data
not shown). However, it should be considered that smoking drives in-
ﬂammation in the lung, and this can lead to DNER induction as well
[19], independently of the presence of the SNP. In contrast to a previous
study showing a positive correlation between gender and DNER expres-
sion,we did not observe any gender nor age effect on DNER levels (Sup-
plementary Fig. 1a-b). Additionally, the use of inhaled corticosteroids
(ICS), a common immunosuppressive medicament for COPD patients,
did not seem to affect lung DNER expression either (data not shown).
These data suggest that the increased DNER expression in COPD lung
homogenates is most likely due to an increase in pro-inﬂammatory
macrophages. Supporting this idea, a very recent proteomic analysis of
sputum from asthmatic patients showed that DNER was increased
among 15 other markers implicated in macrophage-related inﬂamma-
tion [33].
The predominance and contribution of different macrophage sub-
populations to the immunopathogenesis of COPD is unclear, especially
given the complexity and diversity that entails themacrophage popula-
tion [34,35]. Regarding origin, some studies suggest that lung resident
macrophages have greater ability to phagocytose and secrete anti-
inﬂammatory cytokines, meanwhile recruited macrophages tend to
have a more pro-inﬂammatory phenotype. Indeed, it is believed that
Fig. 3.DNER regulates IFNγ secretion in lung recruitedmacrophages during CS-induced chronic inﬂammation. (a) Representative immunoﬂuorescence images of bronchoalveolar lavage
(BAL) cells obtained from ﬁltered air (FA) and 3 day or 2month CS-exposedWT and DNER deﬁcient mice stained to detect DNER (red), Galectin-3 (green) and DAPI (blue) (n=2–3mice
per group). (b) Total IFNγ levels quantiﬁed by ELISA in BAL from FA, 3 day and 2 month CS-exposedWT and DNER deﬁcient mice (n= 4mice per group). (c, d, e and f) Flow cytometric
analysis of Ly6g− F4/80+macrophage populations from thewhole lung of FA and 2month CS-exposedWT and DNER deﬁcient mice (n=4mice per group). (c) Percentage of IFNγ+ cells
gated from Ly6g− F4/80+ macrophages and the MFI of IFNγ staining in the Ly6g− F4/80+ population. (d) Gating strategy for Ly6g− F4/80+ SiglecF+ and SiglecF− populations.
(e) Percentage of IFNγ+ cells gated from SiglecF− Ly6g− F4/80+ macrophages (blue from d) and the MFI of IFNγ staining in the SiglecF− Ly6g− F4/80+ population. (f) Percentage of
IFNγ+ cells gated from SiglecF+ Ly6g− F4/80+ macrophages (burgundy population from d) and the MFI of IFNγ staining in the SiglecF+ Ly6g− F4/80+ population. Two-way ANOVA,
Tukey's multiple comparisons test, *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001. Each data point represents an individual mouse. Data shown mean values ± SD. (b-c, e-f).
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when recruited macrophages enter the inﬂammatory zone, they be-
comeM1 in response to the ongoing insult, contributing to the exagger-
ated production of pro-inﬂammatory cytokines [10]. Concerning the
macrophage phenotypes in the lung, recent reviews point to a direction
of dysfunctionality in both phenotypes,M1 andM2,which results in de-
fective cytokine secretion, migration and efferocytosis [14,15]. Never-
theless, it should be taken into account that the concept of M1/M2
emerged from an in vitro setting where the stimuli are known and sta-
ble [11]. Thus, it becomes controversialwhether there is the existence of
well-deﬁnedM1andM2 subpopulations in a disease context, where the
microenvironment constantly changes [10,34]. Together with the lack
of appropriate markers to track these macrophage subpopulations,
leads us to question whether in vitro ﬁndings can be extrapolated to
what occurs during disease development. Nevertheless, we do believe
that in vivo, a macrophage phenotype can be more pro than anti-
inﬂammatory or vice-versa at a certain time and place, and this is
what we would consider “M1” or “M2” in a disease context.
Several studies have shown that blockade of the Notch pathway im-
proves disease resolution by regulating macrophage polarisation in au-
toimmune and inﬂammatory diseases [36,37]. Most of the published
data consistently supports that Notch promotes a pro-inﬂammatory re-
sponse in macrophages mainly by enhancing TLR and NFκB signalling
[38,39]. Interestingly, our GSEA on monocyte derived macrophages
(MDM) from COPD and healthy subjects showed an enrichment of the
Fig. 4. DNER activates Notch1 signalling in alveolar macrophages from 2 month CS exposed mice. (a) Representative immunoﬂuorescence images of lung tissue from FA and 2 m CS-
exposed WT and DNER deﬁcient mice (n = 3–4 mice per group), Galectin-3 (purple), NICD1 (green) and DAPI (red), high magniﬁcation, scale bars 5 μm; low magniﬁcation, 10 μm.
Yellow squares indicate tissue location of the ampliﬁed macrophages. (b) Quantiﬁcation of Galectin3+ cells showing NICD1+ DAPI overlap (white arrows shown in 4a) from staining
in (a). 12 pictures at 20× magniﬁcation were taken from each mouse sample of each group. Unpaired t-test, **p-value = 0.0055. No signiﬁcant difference was found between FA
groups. (c) Enrichment plots of Notch1 signalling from GSEA analysis of the microarray data fromWT M1 vs DNER deﬁcient M1 BMDM. (d) Enrichment plot of Notch1 signalling from
the GSEA analysis of Monocyte Derived Macrophages (MDM) obtained from healthy and COPD patient microarray data (GSE8608).
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Notch pathway in COPDMDM. Here, we showed that DNER is essential
for a fully functioning IFNγ driven M1 pro-inﬂammatory response in
murine macrophages even though it was not crucial for delineating
the distinct phenotypes.
IFNγ is one of the most upregulated cytokines in the lung of COPD
patients [40,41]. Indeed, COPD MDM showed an enrichment of IFN
pathways compared to healthy subjects. On the one hand, it plays a
key role in promoting inﬂammation and tissue damage by polarising
macrophages and T cells towards a type 1 response [29]. On the other,
it induces bacterial clearance by activating phagocytosis and enhancing
antigen presentation and nitric oxide production, important defence
mechanisms during disease exacerbation [42,43]. Therefore, it should
Fig. 5.Nuclear translocation of Notch1 and NFκB active subunits was abrogated in LPS treated BMDM fromDNER deﬁcientmice. (a) RepresentativeWestern blot of NICD1 protein levels in
cytoplasmic and nuclear extracts of samples fromWT and DNER deﬁcient BMDM treatedwith LPS (1μg/ml) for 24 h and untreated (2 independent experiments, 2/3 biological replicates).
(b) mRNA abundance of Notch receptors (Notch1, Notch2) and ligands (Delta4, Jag1) in the samples from (a). Two-way ANOVA, Tukey's multiple comparisons test, *P b 0.05, ***P b 0.001.
Data shownmean values± SD. (c) Cytoplasmic and nuclear RelB, c-Rel, p105, p50 and p65 from samples described in (a). (d) RepresentativeWestern blots of phosphorylated (p)-IKKα/β,
IKKα and IKKβ from 15min LPS (1μg/ml) treatedWT and DNER deﬁcient BMDM. 2 independent experiments and 2/3 biological replicates, n = 3 (e) Enrichment plot of NFkB signalling
(GO:0051059) following GSEA analysis of the microarray data fromWT M1 vs DNER deﬁcient M1 BMDM.
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be considered that IFNγmay be beneﬁcial as well as detrimental to the
lung. Neutrophils, dendritic cells, NK, B, Th1 and CD8+ T cells are all
known to release IFNγ in response to infections and macrophage-
driven inﬂammation [44,45]. Despite the fact that T cells are the most
common IFNγ-producing cells [46], macrophages are the dominant
cell population in a COPD lung [8], suggesting that macrophage contri-
bution to IFNγ levels is likely considerable. Moreover, macrophages
play a pivotal role in promoting inﬂammation at the early stage of dis-
ease, when IFNγ is involved [42,47,48]. Additionally, high levels of
IFNγ can alleviate tissue injury by inducing TGFβ in macrophages [42]
but it can also induce epithelial cell apoptosis and subsequent emphy-
sema [30]. Thus, the precise regulation of IFNγ in COPD is essential to re-
solve infection without provoking an exaggerated inﬂammatory
response. This would mean that dampening excessive levels of IFNγ,
but not complete abrogation, could improve COPD patient outcomes.
Here, we showed that IFNγ production is abrogated in recruited but
not in resident macrophages from DNER deﬁcient mice during chronic
inﬂammation. In COPD, it has been suggested that recruited macro-
phages tend to acquire a pro-inﬂammatory phenotype, while resident
macrophages become anti-inﬂammatory and pro-resolving cells [49].
Thus one could hypothesize that the blockage of DNER may modulate
IFNγ levels and therefore control the exaggerated immune response in
pro-inﬂammatory macrophages, without affecting the potential beneﬁ-
cial effects that IFNγ could exert in other cell types. Indeed, we showed
that DNER deﬁciency in mice prevented CS induced emphysema and
improved lung function (FEV100), without affecting the percentage or
activation of the immune cell populations.
Currently, the molecular mechanism of non-canonical Notch signal-
ling is controversial and poorly understood. It has been shown that
DNER speciﬁcally interacts with the ﬁrst and second EGF-like repeat of
the extracellular domain of Notch1 by cell-cell contact, and activates
gene transcription in a CSL-independent manner during Bergmann
glia differentiation [21]. In this process, DNER cell location is precisely
controlled by endocytosis to regulate its availability to interact with
other neighbouring cells [50–52]. This explains why DNER, as a trans-
membrane protein, showed a cytoplasmic localisation in our immuno-
ﬂuorescence analysis. Indeed, previous analysis of DNER in neurons,
showed a similar cellular distribution to the one we observe in macro-
phages [50,51].
Non-canonical Notch is characterized for being independent of CSL,
and instead, regulating other signalling proteins such as the NFκB sub-
units [22]. Indeed, the presence of nuclear NICD1 is essential for NFκB
signalling in T cells and macrophages to regulate transcription of pro-
inﬂammatory cytokines. In Th1 cells, interaction of NICD1 with p50
and c-Rel regulates transcription of IFNγ in response to CD3/CD28 co-
stimulation [31,32]. In the case of macrophages, it has been shown
that NICD1 regulates nuclear translocation of NFκB subunits and it is
able to directly bind to TNF and INOS promoters [39,53]. However, the
Notch ligands upstream of these responses remains poorly understood.
It has been suggested that Jag1 and Delta4 can trigger and maintain
Notch signalling by the activation of a positive feedback loop in pro-
inﬂammatory macrophages [54]. In order to undertake molecular stud-
ies to address the DNER induced signalling cascade in activated BMDM,
macrophages were stimulated with LPS alone instead of the combina-
tion with IFNγ as performed for M1 polarisation, since IFNγ activates
other pathways and a positive feedback loop [44], that couldmake it dif-
ﬁcult to interpret the results. In contrast to previous studies, our data re-
vealed that induced levels of Jag1 and Delta4 in LPS treated DNER
deﬁcient BMDM are not able to compensate for the reduction in IFNγ
expression. Here, we showed that the non-canonical Notch ligand
DNER regulates IFNγ transcription via NICD1 and NFκB signalling in pri-
marymurinemacrophages upon LPS stimulation and in vivo chronic in-
ﬂammation. Supporting these ﬁndings, quantiﬁcation of triple nuclear
NICD1+ macrophages, revealed that DNER deﬁcient 2 month CS-
exposedmice exhibited reduced nuclear NICD1 translocation compared
to WT macrophages which was accompanied by impaired nuclear
translocation of the NFκB subunits in LPS stimulated BMDM from
DNER deﬁcient mice. In keeping with NFκB regulating the expression
of the majority of cytokines in activated macrophages [55], gene levels
of NFκB downstream targets, aside from IFNγ, was observed to be
dampened in DNER deﬁcient M1 macrophages as evidenced by GSEA
and predictive upstream regulator analysis. Nevertheless, we would
have expected a more pronounced reduction in cytokine expression
given the strong abrogation of NFκB in LPS-treated DNER deﬁcient
BMDM. However, it should be taken into account that other key path-
ways for cytokine expression like MAPK cascade, ERK or JAK/STAT1
could partially compensate the absence of NFκB activation [56].
Taken all together, we speculate that exposure of lung recruited
macrophages to the ongoing inﬂammatory insult during COPD progres-
sion, leads to increased levels of DNER and subsequent induction of IFNγ
expression via a non-canonical Notch NFκB cross talk pathway in
Notch1positivemacrophages (Fig. 6). This studynot only adds newmo-
lecular insights to the complexity of Notch and the involvement of non-
canonical signalling in COPD pathogenesis, but also opens new direc-
tions to further investigate novel targets for the treatment of COPD.
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Healthy COPD 
Subjects (n) 10 15 
Mean age years 45.7 ± 4.65 57.2 ± 1.31 
Sex 
Male 6 6 
Female 4 9 
Height (m) 1.72 ± 0.03 1.64 ± 0.02 
Weight (kg) 77 ± 4.22 60.4 ± 3.21 
Smoking (packs/year)   41.6 ± 7.57 
FEV1 (%)   35 ± 5.89 
FVC (%)   83.35 ± 6.24 
FEV1/FVC (%)   33.80 ± 3.10 
Bronchodilators only (subjects) 4 (26.6%) 
Bronchodilators + ICS (subjects) 10 (66.6%) 
Supplementary Table 1 
Gene Forward primer Reverse Primer 
DNER CGA CCT GTG CCC AGC TTA TT AGG CCA TGG TAA CCT GGA TCA 
TNF GCC TCT TCT CCT TCC TGA TCG AGC TTG AGG GTT TGC TAC AAC A 
HPRT1 AGG AAA GCA AAG TCT GCA TTG TT GGT GGA GAT GAT CTC TCA ACT TTA A 
Dner AAT GGC ACT TGC TAC GTG GA GGC CAT GGT AAC CTG GAT CG 
Tnf CAC CAC GCT CTT CTG TCT GGC TAC AGG CTT GTC ACT C 
Il12p35 ACT AGA GAG ACT TCT TCC ACA ACA AGA G GCA CAG GGT CAT CAT CAA AGA C 
Fizz1 TGC CAA TCC AGC TAA CTA TCC C ACG AGT AAG CAC AGG CAG TT 
Arg1 GGA ACC CAG AGA GAG CAT GA TTT TTC CAG CAG ACC AGC TT 
Ifnb1 CAG CTC CAAG AAA GGA CGA AC GGC AGT GTA ACT CTT CTG CAT 
Ifng TCA AGT GGC ATA GAT GTG GAA GAA TGG CTC TGC AGG ATT TTC ATG 
Notch1 ACA GTG CAA CCC CCT GTA TG AGT TGT TCC GTA GCT GGT CG 
Notch2 AGC AGG AGG TGA TAG GCT CT TGG GCG TTT CTT GGA CTC TC 
Jag1 AGC CAA GGT GTG CGG G ACG CGG GAC TGA TAC TCC TT 
Delta4 TTC CAG GCA ACC TTC TCC GA ACT GCC GCT ATT CTT GTC CC 
Hprt1 AGC TAC TGT AAT GAT CAG TCA ACG AGA GGT CCT TTT CAC CAG CA 
Tbet TCA GGA CTA GGC GAA GGA GA TAG TGG GCA CCT TCC AAT TC 
Gata3 GTC ATC CCT GAG CCA CAT CT TAG AAG GGG TCG GAG GAA CT 
Rorgt TTTGGAACTGGCTTTCCATC AAGATCTGCAGCTTTTCCACA 
Foxp3 AGA GCC CTC ACA ACC AGC TA CCA GAT GTT GTG GGT GAG TG 
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Supplementary Figure 2
b ca
f
Enriched genes in IFN? signalling dataset (from Fig 2F)
500bp
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WT    Dner-/-
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M0         M1
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GENE 
SYMBOL
RANK METRIC 
SCORE
RUNNING ES
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ENRICHMENT
IFNGR1 0,555793166 0,016395938 Yes
SUMO1 0,555555582 0,06843433 Yes
FCGR1A 0,548780501 0,11730901 Yes
OAS2 0,476190478 0,14225388 Yes
PTAFR 0,454545468 0,17979813 Yes
PTPN1 0,384615391 0,18147604 Yes
GBP5 0,33427763 0,18348804 Yes
OAS1 0,317919075 0,20190263 Yes
PRKCD 0,306122452 0,22340244 Yes
JAK2 0,294117659 0,24346457 Yes
SOCS3 0,292035401 0,2672922 Yes
IFNGR2 0,276280522 0,28188163 Yes
VCAM1 0,255033553 0,28695264 Yes
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GENE 
SYMBOL
RANK METRIC 
SCORE
RUNNING 
ES
CORE 
ENRICHMENT
HDAC3 1.296296239 0.1251865 Yes
CREBBP 0.814317822 0.19795468 Yes
HIF1A 0.518518507 0.20764284 Yes
null 0.483870953 0.24362169 Yes
HDAC2 0.47356829 0.28676453 Yes
TLE4 0.434964508 0.3138684 Yes
MYC 0.333333343 0.2899674 Yes
NCOR1 0.32764855 0.3188046 Yes
TLE2 0.3125 0.33849412 Yes
SNW1 0.263157904 0.32508263 Yes
HDAC1 0.257731944 0.3445112 Yes
HDAC10 0.2360515 0.3449183 Yes
TBL1X 0.217391297 0.3469396 Yes
- 3.066 GENE 
SYMBOL
RANK METRIC 
SCORE
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ENRICHMENT
HDAC3 1.296296239 0.20311034 Yes
FOXP3 0.555555582 0.2531114 Yes
RELA 0.543243885 0.33511746 Yes
HDAC2 0.47356829 0.38970152 Yes
RPS3 0.428571433 0.43746465 Yes
COMMD7 0.373134315 0.46795464 Yes
ANXA4 0.263157904 0.43196097 Yes
HDAC1 0.257731944 0.4682062 Yes
FAF1 0.209026173 0.4539978 Yes
PPARD 0.196257785 0.47010383 Yes
TAF4B 0.175315574 0.47596845 Yes
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Supplementary Fig. 1. DNER expression in human lung and murine bone marrow derived dendritic cells. (a)
Lung DNER mRNA levels in males versus females subjects used in Fig. 1a. One-way ANOVA. (b) Correlation
between age and DNER expression in human samples used in Fig. 1a. Spearman test. (c) Representative picture
of immunofluorescence staining of DNER and Galectin 3 in lung tissue from an additional COPD patient. (d)
BMDM characterization by FACS analysis with markers for macrophages (F4/80, CD11b), DC (Ly6c, CD11c)
and neutrophils (Ly6g). 1 experiment, n=1. (e) Dner and Ifng mRNA abundance in 24h LPS (1?g/ml) treated
murine bone marrow derived dendritic cells isolated from WT mice. 1 experiment, n=5. Unpaired t-test,
*p=0.0213. Data shown mean values ± SD.
Supplementary Fig. 2. Efficiency of Dner deletion in C57BL/6 mice and cellular phenotype of Dner-/-
BMDM. (a) Schematic representation of Dner gene deletion strategy in Dner deficent mice. (b) Dner mRNA
abundance in brain tissue and untreated or M1 (LPS 1????? + IFN?) BMDM from WT and Dner deficient mice
quantified by end point PCR. (c) Protein levels of Dner in brain and lung tissue from WT and Dner deficent
mice. (d) Principal component analysis of Dner-/- vs. WT BMDM microarray data. (e) mRNA levels of M1
(Tnf, Il-12a) and M2 (Arg1, Fizz1) markers in WT and Dner deficient BMDM. Two-way ANOVA, Tukey’s
multiple comparisons test, **p<0.01, ****p<0.0001. Data shown mean values ± SD. (f) List of genes enriched
in WT M1 from the ???? signaling dataset of the GSEA analysis shown in Fig. 2f.
Supplementary Fig. 3. The pathophysiological and immunophenotypic analysis of Dner deficient mice after
CS exposure. (a) Schematic representation of experimental design. (b) Forced expiratory volume after 100ms
of FA and 2 months CS exposed Dner deficient and WT mice. (c) Mean chord length measurement of lung
tissue sections from same samples as in b. (d) Percentages of innate immune cell populations in whole lung
from FA, 3 days and 2 month CS-exposed WT and Dner deficient mice analyzed by flow cytometry. (e) Cell
numbers and MFI values of adaptive immune cell populations in whole lung from samples shown in e. (f)
mRNA levels of positive markers for in vitro differentiated T cell subpopulations: Th1 (Tbet), Th2 (Gata3),
Th17 (Rorgt) and Treg (Foxp3) (see more details in materials and methods). n=2/3, 1 experiment. (g) Dner
expression in T cell subpopulations from f. Two-way ANOVA, Tukey’s multiple comparisons test, *p<0.05,
**p<0.01, ***p<0.001, ****P<0.0001. (b-e). One-way ANOVA, Tukey’s multiple comparisons test, Th1***p-
value=0.0008, Th2 *p-value=0.0231, Th17** p-value=0.0019, Treg** p-value=0.0048 (f-g). Data shown mean
values ± SD.
Supplementary Fig. 4. Gene datasets of enriched Notch1 and NFKB signalling in M1 WT BMDM compared
to Dner deficient M1 BMDM. a) List of enriched genes in WT M1 BMDM from the Notch1 pathway dataset
of the GSEA analysis shown in Fig. 2C. b) ???? cytokine concentration in cell supernatants obtained from WT
and Dner deficient BMDM treated with LPS (1ug/ml) for 24h and untreated (2 independent experiments, n=3).
Two-way ANOVA, Tukey’s multiple comparisons test, *p<0.05. Data shown mean values ± SD. c) Enriched
genes in WT M1 BMDM from NFKB binding dataset (GO:0051059) from the GSEA analysis of the WT M1
vs Dner deficient M1 microarray data . d) Upstream regulator prediction based on 614 significantly (p<0.05)
regulated genes between Dner deficient M1 vs WT M1 in our microarray analysis. The plot represents the top 9
inhibited regulators with the lowest activation z-scores.
Supplementary Table 1. Demographics and clinical characteristics of healthy and COPD transplant patients
(Mean ± SEM). FEV1: Forced expiratory volume in the first second; FVC: Forced vital capacity; ICS: inhaled
corticosteroids.
Supplementary Table 2. Primer sequences used for RT-PCR.
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Female mice lacking ????? exhibit 
endothelial cell apoptosis and 
emphysema
Isabel Egaña?, Hiroshi Kaito?, Anja Nitzsche  ????, Lore Becker???, Carolina Ballester-Lopez???, 
Colin Niaudet?, Milena Petkova?, Wei Liu?, Michael Vanlandewijck?, Alexandra Vernaleken???, 
Thomas Klopstock  ???????, Helmut Fuchs  ?, Valerie Gailus-Durner?, Martin Hrabe de Angelis 
 ??????, Helge Rask-Andersen?, Henrik J. Johansson  ??, Janne Lehtiö  ??, Liqun He?, Ali Ö. 
Yildirim???, Mats Hellström? & German Mouse Clinic Consortium*
Paladin (?????, ????????????????????? ????????????????????????????????????????????????????????????
putative phosphatase. Paladin has also been proposed to be involved in various biological processes 
??????????????????????????????????? ??????????? ???????????? ?????????? ?? ?????????????????????????????
we have now characterized the ???????????????? ?????????? ??????????? ?? ?????????????????????????
???? ?????????????????? ????? ???????????????????? ??????? ????? ???? heterozygous and homozygous 
knock-out mice display an emphysema-like histology with increased alveolar air spaces and impaired 
?????????????? ????????????????????????????????????????????? ???? ????????????? ????? ???? is restricted 
to the vascular compartment, ????? is expressed in both the epithelial and mesenchymal compartments 
??????????????????????? ??????????? ?????????????????????????????????????????????????????????????????????
?????????????? ???????????????????????????????? ?????????????????????? ?????????????????????????????????????
???????????????????????????? ?????????????? ??? ?????????????????? ???? is required during lung vascular 
???????????????????? ?????????????????????? ?????????????????????????????????????????? ??????? ??????
??????????????????????? ??????????? ????????????????????????????????????????????????????
Paladin or Pald1 is a phosphatase-domain containing protein and we have identiﬁed it in two independent 
screens for novel regulators of angiogenesis and vascular function1,2. Pald1 expression is prominent in developing 
endothelial cells during early embryonic development and, in certain vascular beds, Pald1 expression shi#s to 
mural cells as the vasculature matures, e.g. in the CNS3. Furthermore, Pald1 was also found in hematopoietic 
cells and other non-vascular cells, such as neural crest cells3,4. A role of Pald1 as a regulator for neural crest cell 
formation and migration in the chick embryo has been shown by morpholino knock-down experiments. It was 
suggested that Pald1 would not require any catalytic activity for its role in neural crest migration since mutation 
of the putative catalytic cysteine to serine still aﬀected neural crest migration a#er over expression4.
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Pald1 has also been shown to negatively regulate expression and phosphorylation of the insulin receptor, as 
well as phosphorylation of its downstream target kinase Akt in cell culture, even though no phosphatase activity 
could be detected in vitro5. Pald1 has therefore been proposed to be a pseudo-phosphatase, and as such been 
implicated to indirectly regulate cell signaling5–7. However, others have predicted that Pald1 can possess catalytic 
activity, even though this have not been shown experimentally yet8. Furthermore, Pald1 has been suggested to 
aﬀect another type of receptor signaling, acting as a negative regulator of Toll-like receptor 99.
While there is a strong expression of Pald1 in both the prenatal and adult lung3, its role in lung develop-
ment or function is unknown. A central role for angiogenesis has been proposed for lung diseases like chronic 
obstructive pulmonary disease (COPD) and emphysema10. COPD is a chronic progressive disease characterized 
by clinical symptoms such as dyspnea and coughing, due to obstruction of the airways. COPD is a major cause 
of death worldwide and it is estimated that COPD will become the third leading cause of death by 202011,12. 
COPD is frequently accompanied by emphysema, i.e. the destruction of the alveolar walls and the consequen-
tial dilation of the distal airways10. Alterations of mRNA and protein expression of vascular endothelial growth 
factor A (VEGF-A) and its receptor VEGF receptor 2 (VEGFR2) are associated with patients exhibiting COPD 
and emphysema13. Experimental disruption of VEGF-A/VEGFR2 signaling has also been shown to be suﬃcient 
to induce emphysema and COPD-like changes in mice and rats through apoptosis14–16. &ere are sex-speciﬁc 
diﬀerences in COPD and emphysema in humans where subsets of women develop more severe emphysema than 
men. Female smokers with early onset COPD or severe emphysema have smoked signiﬁcantly less than their 
male counterparts17. It has also been shown that female mice develop earlier and more severe emphysema than 
male mice in response to cigarette smoke18. However, the mechanisms responsible for this apparent sex-linkage 
remain unclear.
Here we describe the phenotype of Pald1+/− and Pald1−/− mice19,20 and characterize lung defects linking Pald1 
to sex-speciﬁc endothelial cell apoptosis, development of emphysema and COPD-like changes in females. To our 
knowledge, this is the ﬁrst report of a sex-speciﬁc eﬀect on endothelial cell apoptosis.
Results
?????−/− mice exhibit an obstructive lung phenotype. In order to characterize the Pald1−/− mouse, 
we performed a wide array of behavioral, physiological and biochemical tests at the German Mouse Clinic 
(GMC). Although most of the results turned out normal for Pald1−/− mice (Table S1 and Figure S1), it was note-
worthy that female, but not male, Pald1−/− mice exhibited increased lung volumes and compliance and decreased 
resistance, which are changes also observed in elastase-induced emphysema mouse model21 (Table 1).
Paladin is expressed broadly in the adult lung. We have previously shown that Pald1 protein is abun-
dant in the mesenchymal compartment of embryonic lungs and that Pald1 is also highly expressed in the adult 
lung3. Single cell sorting and sequencing from mouse embryonic lung strongly supports the conclusion that Pald1 
is exclusively expressed in endothelial cells during embryonic development22,23.
To begin to understand the role of Pald1 in postnatal lung development and function, we mapped Pald1 expres-
sion in detail. We analyzed the expression at three distinct time points during postnatal development and in the 
adult, postnatal day 5 (P5), 4 and 19 weeks of age as it covers main aspects of postnatal development of the major gas 
exchange unit of the lungs – the alveoli. &e tremendous increase in gas exchange surface that occurs postnatally by 
formation of alveoli is accelerated from P5 until 2 weeks of age and peaks at 5–6 weeks. It is then stable until 40 weeks 
of age, and subsequently there is a gradual loss of alveoli. &e decrease in alveolar septal thickness, that also facilitates 
gas exchange, continues from P5 until 4 weeks of age. &erefore, we decided to map the expression of Pald1 and 
assess the phenotype of Pald1−/− animals at P5, 4 and 19 weeks of age, to cover the dynamic process of postnatal lung 
development24. First we isolated single endothelial cells and pneumocytes type II from lungs using mT/mG reporter 
mice expressing Cre-recombinase under the endothelial Tie2 promoter and under the pneumocyte type II-speciﬁc 
surfactant protein C (SPC) promoter, respectively25,26. mRNA isolation and quantitative PCR for Pald1 showed that 
Pald1 is expressed in endothelial cells, but also in type II pneumocytes (Fig. 1a). To map the expression of Pald1 at 
cellular resolution, we took advantage of the LacZ reporter of Pald1 knock-out construct3. Murine Pald1 heterozy-
gous (Pald1LacZ/+) and homozygous mutant (Pald1LacZ/LacZ) lungs were harvested at postnatal day (P) 5, week 4 and 
week 19. &e LacZ reporter indicated a broad expression of Pald1 in the murine lung in both males and females 
across all ages analyzed apart from bronchiolar epithelium. LacZ expression pattern was the same in Pald1LacZ/+ and 
Pald1LacZ/LacZ lungs (Fig. 1b and Figure S2). Combining LacZ staining with antibodies speciﬁc for each of the main 
cell types in the alveoli revealed that Pald1 can be detected at all stages in the endothelial cells forming the capillaries 
around the alveoli but is less frequently detected in the endothelium of larger vessels (Fig. 2, and Figure S3). Paladin 
was also detected in vascular smooth muscle cells, macrophages, pneumocytes type I and II and Platelet-derived 
Growth Factor Receptor α (PDGFRα)-positive mesenchymal cells (Fig. 2). However, the surfactant protein positive 
type II pneumocytes were not LacZ positive at P5.
Taken together, Pald1 mRNA and protein are strongly expressed in endothelial cells as well as in other cell 
types in the postnatal lung, except for bronchial epithelial cells.
??????????????????????????????????????????????????????????? ????? COPD in humans is often 
accompanied by emphysema, characterized by destruction of alveolar walls and distal airspace enlargement27. 
Histological analysis of Pald1 wild type and knock-out lungs revealed enlarged distal airspaces in female mice, 
but not in males, assessed by both blinded lung pathologist and quantiﬁcation of mean linear intercept (MLI) 
(Fig. 3a–c). Increase in MLI, i.e. increase in distance between airway walls, was seen already at P5, at the end of 
the saccular stage and before alveolarization28. &e distal airway dilation was still present at 4 and 19 weeks of 
age. Interestingly, we observed that female Pald1+/− mice also exhibited a signiﬁcant increase in distal airspace 
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enlargement as quantiﬁed by MLI (Fig. 3d). However, no diﬀerence in alveolar septal thickness was detected 
(Pald1+/+ 2,67+/− 0,14 vs. Pald1−/− 2,48+/−0,07 µm3/µm2, P = 0,13).
?????????????????????????????????????????????????????????????????????????????????????????? 
knock-out lungs. To further dissect the lung phenotype of female Pald1 knock-out mice, we used cell 
type-speciﬁc markers to assess the relative contribution in the lung. Cell type-speciﬁc markers for pneumocytes 
type I or II, macrophages or PDGFRα-positive cells did not reveal any diﬀerences of cell number between wild 
type and Pald1 knock-out mouse lungs over time (Fig. 4c–e and Figure S4). However, using the endothelial cell 
nuclei-speciﬁc marker Erg showed a reduction of endothelial cell number in the vascular compartment in females 
at 4 weeks of age by 14% (Fig. 4a and b).
Given the reduced number of endothelial cells at 4 weeks, we determined the frequency of apoptotic cells 
by cleaved caspase-3 (CC3) staining in both endothelial and non-endothelial cells in these lungs (Figure S5). 
&ere was a more than six-fold increase in apoptotic cells (0.75% ± 0.41% (SD) vs. 4.90% ± 0.76% CC3+ cells, 
p < 0.0001) in the endothelial compartment in female Pald1−/− compared to Pald1+/+ mice at 4 weeks of age. 
However, there were no diﬀerences in non-endothelial cell apoptosis or apoptosis comparing male wild type 
and knock-out mice. &e increase in cleaved caspase-3 was still more than two-fold at both P5 and 19 weeks of 
age comparing wild type and knock-out Pald1 females (Fig. 5a and b). &e enhanced endothelial apoptosis in 
female Pald1−/− was also accompanied by an increase of proliferation, as assessed by Ki-67 staining (Fig. 5c and 
Figure S5).
???????????????????????????????????????????????????????????? To begin to understand the mech-
anism of sex-speciﬁc phenotype in Pald1 knock-out lungs, we employed lung proteome analysis using mass 
spectrometry based proteomics29. We identiﬁed in total 10099 proteins at 1% protein false discovery rate, and 
8,635 proteins were quantiﬁed in all 16 lung samples (n = 4 per sex and genotype) from 4 weeks old mice. One 
female Pald1 knock-out sample was excluded from further analyses because of contamination as described in 
Female Male
Pald1+/+ (n = 6) Pald1−/− (n = 6) p-value Pald1+/+ (n = 7) Pald1−/− (n = 5) p-value
Median Median Median Median
[25%; 75%] [25%; 75%] [25%; 75%] [25%; 75%]
Body weight (g)
26.2 25.6 0.623 34.9 33.4 0.093
[24.4, 27.7] [23.6, 27.4] [34.1, 36.4] [32.8, 33.0]
Tidal volume (ml)
0.21 0.22 0.056 0.19 0.20 0.374
[0.21, 0.21] [0.22, 0.22] [0.18, 0.21] [0.20, 0.20]
Inspiratory capacity (ml)
0.695 0.885 0.026 0.871 1.340 0.026
[0.650, 0.755] [0.832, 0.982] [0.650, 0.755] [1.320, 1.253]
Expiratory Reverse Volume (ml)
0.26 0.29 0.323 0.24 0.26 0.425
[0.25, 0.29] [0.28, 0.30] [0.21, 0.26] [0.24, 0.28]
Vital Capacity (ml)
0.97 1.17 0.026 1.23 1.09 0.779
[0.90, 1.01] [1.12, 1.29] [0.90, 1.46] [1.12, 1.29]
Functional Residual Capacity (ml)
0.295 0.310 0.370 0.325 0.295 0.980
[0.290, 0.308] [0.292, 0.328] [0.329, 0.369] [0.275, 0.365]
Residual Volume (ml)
0.025 0.035 0.649 0.029 0.056 0.649
[0.020, 0.053] [0.030, 0.040] [0.025, 0.035] [0.030, 0.040]
Total lung capacity (ml)
1.005 1.190 0.022 1.472 1.695 0.096
[0.962, 1.032] [1.137, 1.302] [1.362, 1.532] [1.137, 1.859]
Forced Vital Capacity (ml)
0.895 1.065 0.026 1.099 1.160 0.323
[0.828, 0.925] [1.015, 1.175] [0.828, 1.125] [1.015, 1.175]
Forced Expiratory Volume in 100 ms 
(ml)
0.885 1.030 0.028 1.058 1.097 0.507
[0.802, 0.915] [0.982, 1.145] [0.976, 1.129] [0.872, 1.201]
Peak Expiratory Flow (ml/sec)
30.1 30.7 0.141 33.6 31.7 0.092
[30.1, 30.5] [30.6, 30.9] [33.1, 34.5] [30.8, 32.7]
Static lung compliance (ml/cm H2O)
0.050 0.070 0.039 0.056 0.053 0.384
[0.050, 0.058] [0.063, 0.070] [0.051, 0.059] [0.051, 0.055]
Dynamic lung compliance (ml/cm H2O)
0.02 0.03 0.015 0.04 0.03 0.370
[0.02, 0.02] [0.03, 0.03] [0.03, 0.05] [0.03, 0.03]
Resistance (cm H2O/ml/sec)
1.40 1.27 0.013 0.98 1.11 0.652
[1.35, 1.45] [1.23, 1.31] [0.96, 1.11] [1.01, 1.31]
Table 1. Functional lung tests in 20-week old Pald1+/+ and Pald1−/− mice. Lung function was assessed by 
a forced maneuver system and a Fine-Pointe RC system. Diﬀerences between genotypes were evaluated by 
Wilcoxon test. Data are presented as median values ± interquartile range.
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Materials and Methods. Hierarchical clustering based on the expression of all proteins showed that the major 
factor for clustering is sex, and not genotype (Fig. 6a). &ree proteins including Pald1 showed signiﬁcantly altered 
expression between wild type and knock-out mice in a sex-independent manner. Hpgd (hydroxyprostaglandin 
Figure 1. Paladin has a broad expression in the postnatal lung. (a) Endothelial cells and pneumocytes type II 
were isolated from lungs of mT/mG mice expressing endothelial-speciﬁc Tie2-Cre (le#) or pneumocyte type 
II-speciﬁc SPC-Cre (right). Q-PCR of sorted single cells indicates Pald1 mRNA expression in both endothelial 
cells and non-endothelial cells, including pneumocytes type II, both at 3 weeks and 3 months of age. Expression 
was normalized to 18 S RNA. (b) Pald1 LacZ reporter activity (blue) is detected in Pald1LacZ/LacZ mice, 5 days, 4 
weeks and 19 weeks a#er birth. LacZ is broadly expressed in the lung tissue, except for the bronchial epithelium, 
which shows no reporter activity (arrow). Scale bar = 200 µm.
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Figure 2. Paladin is expressed both in the epithelial and mesenchymal compartment of the postnatal lung (4 
weeks). (a–e) Combined X-gal (black) and immunoﬂuorescence staining of Pald1LacZ/LacZ mice show Pald1 LacZ 
expression in the vasculature, i.e. endothelial cells in capillaries (a) but to a lesser extent in endothelial cells of 
larger blood vessels (b) as indicated by Erg staining (endothelial cell nuclei, green). In large blood vessels LacZ 
expression can be detected in vascular smooth muscle cells (c, α-smooth muscle actin, red). Paladin LacZ 
reporter is also active in pneumocytes type II (d, SPC, green) and pneumocytes type I/II (e, cytokeratin, red). 
Scale bar = 20 µm.
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dehydrogenase 15 (NAD)), showed higher expression in knock-out lungs than wild type, which was conﬁrmed 
by Western blot (Fig. 6b and Figure S6). In addition, Mycbp2, MYC binding protein 2, as well as Pald1 was signif-
icantly down regulated (Figure S7). &e most diﬀerentially expressed protein between wild type male and female 
lungs was HSD17B7, a protein essential for cholesterol biosynthesis and with the capacity to catalyze conversion 
of estrone to estradiol30. &ere were no statistically signiﬁcant protein expression changes that were speciﬁc to 
female knock-out mice, a#er correction for multiple testing.
Discussion
Several independent groups have identiﬁed Pald1 as a vascular enriched gene1,2,31 and we have previously shown 
that Pald1 is expressed in both endothelial and mural cells in the vasculature3.
Extensive phenotypic screening revealed morphological and functional lung defects in female Pald1−/− mice. 
&is was accompanied by increased distal air spaces and elevated apoptosis and proliferation exclusively in the 
endothelial compartment of female mice. It is tempting to speculate, that Pald1 has a unique role in the vascu-
lature of the lung, as this is where we observe the strongest phenotype, even though the expression of Pald1 is 
broader and we cannot exclude that the increased endothelial turnover is secondary to alteration in other cell 
types.
Figure 3. Pald1−/− mice show reduced complexity of the lung tissue. (a,b) Dark ﬁeld images of distal airspace 
from 4 weeks old female Pald1 wild type (a) and knock-out animals (b), suggest a general airspace enlargement 
in the Pald1 knock-out lungs. Scale bars = 200 µm. (c) Quantiﬁcation of interseptal alveolar distance using 
Mean Linear Intercept (MLI) of hematoxylin-eosin stained lung tissue at P5 (n = 3), 4 (n = 5) and 19 weeks 
(n = 4) shows increased air spaces in female knock-out animals at all stages, but was particularly increased at 4 
weeks. ANOVA per age group: P5 p < 0.0001; 4 weeks p = 0.0002; 19 weeks p = 0.0004. Pald1−/− was compared 
to Pald1+/+ of the same sex within each age group. (d) MLI of Pald1 wild type, heterozygous and knock-out 
female mice at the indicated ages. ANOVA per age group: 4 weeks p = 0.0001, 19 weeks p = 0.0007. Pald1−/− 
and Pald1+/− were compared to Pald1+/+ within each age group. Error bars: SD, *p ≤ 0.05, ***p ≤ 0.001, 
****p ≤ 0.0001.
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A central role for endothelial cell apoptosis in the development of emphysema has been proposed. &is is 
based on both the correlation of increased endothelial cell apoptosis and down regulation of VEGF in human 
patients exhibiting emphysema13, and experimental evidence in animal models. Genetic ablation of VEGF-A 
in the lung using adenoviral Cre led to endothelial and non-endothelial cell apoptosis, without a compensatory 
increase in proliferation16. Inhibition of VEGFRs using either low molecular weight kinase inhibitors or speciﬁc 
VEGFR2 (but not VEGFR1) blocking antibodies was also suﬃcient to trigger alveolar apoptosis and develop-
ment of emphysema in mice and rats14,15. In addition, direct induction of lung endothelial cell apoptosis using an 
endothelial-homing peptide triggers development of emphysema32, suggesting that alveolar structures cannot be 
maintained without endothelial cells, as well as that endothelial cell apoptosis in the lung culminates in emphy-
sema. Comparison of MLI measurements in the above-mentioned VEGF-A/VEGFR2 targeted mice and rats 
shows that the emphysema development in Pald1−/− female mice is comparable to what is seen in those models. 
However, alterations of VEGF and VEGFR levels were not the reason to emphysema in the Pald1 knock-out mice 
as no diﬀerences in VEGFA or VEGFR2 protein levels were detected in the proteomic analysis, or by western blot.
Figure 4. Pald1−/− show a decrease in the endothelial cell population at 4 weeks. (a–e) Quantiﬁcation of the 
relative proportion of endothelial cells (a,b, Erg, n = 3–5), pneumocytes type II (c, SPC, n = 3), pneumocytes 
type I/II (d, cytokeratin, n = 3), and macrophages (e, CD68, n = 3–7). &e speciﬁc cell type contribution was 
unaltered in Pald1−/− mice except for a 15% decrease of the endothelial cell population at 4 weeks in Pald1−/− 
mice. Scale bar = 20 µm, Error bars: SD, t-test between genotypes of each age group. ***p ≤ 0.001.
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&e increase in distal airspace in female Pald1 knock-out mice is stable from early postnatal stage to 19 weeks 
of age. &e mechanism of airspace enlargement must be distinct from emphysematous development in adult 
humans as it occurs already before alveolar septation and is non-progressive. Despite this, further studies into 
this phenotype, might provide additional information on what type of cellular changes and biochemical pathways 
that can lead to the end stage phenotype that we refer to as emphysema. Further studies will also be necessary 
to pinpoint the mechanism whereby Pald1 regulates endothelial cell survival and proliferation in a sex-speciﬁc 
fashion. &e proteomics data showed that sex, but not genotype, was the most signiﬁcant factor for diﬀeren-
tial protein expression. &is is consistent with the accumulating evidence regarding sex diﬀerences and lung 
biology33. Somewhat surprisingly, no speciﬁc protein expression diﬀerences were detected between female wild 
type and knock-out lungs. However, Hpgd, the major enzyme for degradation of prostaglandins, showed higher 
expression in all knock-out lungs compared to wild type, irrespective of sex. Given that prostaglandin signaling 
is abundant and important for lung and vascular function as well as angiogenesis34, it could be speculated that 
prostaglandin signaling is associated with the emphysema phenotype, but that the Pald1−/− males are somehow 
protected. &e lack of signiﬁcant protein changes between female wild type and knock-out lungs, despite of the 
morphological diﬀerences and endothelial apoptosis observed at the time point analyzed, could be due to several 
reasons including sensitivity of the proteomics screen, use of complex tissue containing several cell types and/or 
due to time point of analysis. Even though we observe the greatest morphological changes at 4 weeks of age, the 
potential protein expression diﬀerences causing those changes might have occurred earlier.
Paladin was previously identified as a negative regulator of insulin signaling by in vitro screening for 
FOXO1A-driven reporter gene expression using a human cDNA library5. We detected a minor reduction in the 
ability to clear glucose from the blood stream in male mice as assessed by an intraperitoneal glucose tolerance 
test (Table S1). However, this is in contrast to the reported negative eﬀect of Pald1 on insulin receptor signaling in 
cells. Further studies will be needed to determine the signiﬁcance of this ﬁnding.
It was reported that Pald1 modulated the expression of key regulatory genes in neural crest development, and 
plasmid mediated over expression and morpholino-based knock-down of Pald1 delayed neural crest migration 
in the chick embryo4. Even though we have noted a prominent expression of Pald1 in migrating neural crest cells 
during embryonic development3, we have not noted any diﬀerences in neural crest derived tissues such as cardiac 
outﬂow tract, melanocytes, cranial bones or myelination in adult Pald1−/− mice. However, a transient role of 
Pald1 in neural crest migration during development has not been assessed.
Figure 5. Increased apoptosis and proliferation of endothelial cells in Pald1 knock-out female lungs. (a,b) 
Quantiﬁcation of cleaved caspase-3 positive (CC3+) cells in 4 and 19-week old lungs revealed a signiﬁcant 
increase in the number of cleaved caspase-3 positive endothelial cells (Erg positive) at 4 weeks of age and at 
19 weeks in female (a, n = 3–4), but not in male Pald1−/− mice (b, n = 3–4). &ere was no signiﬁcant increase 
in non-endothelial cells (Erg negative) at both 4 and 19 weeks. (c,d) Quantiﬁcation of Ki67 positive cells in 4 
and 19-week old lungs revealed an increased number of Ki67-positive endothelial cells (Erg positive) in female 
(c, n = 3–4), but not in male Pald1−/− mice (d, n = 3–4). &ere was no signiﬁcant increase in non-endothelial 
cells (Erg negative) at both 4 and 19 weeks. Error bars: SD, t-test between genotypes within each age group. 
* = p ≤ 0.05, **** = p ≤ 0.0001.
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Taken together, our comprehensive description of the Pald1−/− mouse revealed that the putative phosphatase 
Pald1 plays a role in the development and function of the lung, and speciﬁcally in female pulmonary endothelial 
cell survival and proliferation. Further studies are necessary to address how the lack of Pald1 leads to endothelial 
cell apoptosis and proliferation, and how that is related to the emphysema phenotype in a sex-speciﬁc manner.
Materials and Methods
Paladin nomenclature and mouse model. Paladin is encoded by Pald1 (phosphatase domain contain-
ing, paladin 1, also known as x99384 or mKIAA1274) in mice. C57BL/6 mice with constitutive deletion for Pald1 
(Exon 1–18 replaced by a LacZ reporter cassette) have been generated3 and backcrossed for 10 generations. ROSA 
mT/mG × Tie2-Cre mice35 were generated as previously described25. ROSA mT/mG mice (Jackson Stock 007576) 
were crossed to S#pc-Cre26 to generate ROSA mT/mG × S#pc-Cre. All animal experiments were performed in 
accordance with the relevant laws and institutional guidelines and were approved by the Uppsala University 
board of animal experimentation. At the GMC mice were maintained in IVC cages with water and standard 
mouse chow according to the GMC housing conditions and German laws. All tests performed at the GMC were 
approved by the responsible authority of the district government of Upper Bavaria, Germany.
FACS and quantitative PCR. Isolation of single cells from ROSA mT/mG × Tie2-Cre and ROSA mT/
mG × S#pc-Cre lungs by FACS, mRNA extraction and quantitative PCR was done as previously described25.
Western blot analysis. Snap frozen lungs from 2, 3 and 22-week old mice were lysed in 20 mM HEPES, 
150 mM NaCl, 1% NP40, 1x protease inhibitor cocktail (Roche), homogenized with Tissue Tearor (BioSpec 
Figure 6. Proteomics data overview and signiﬁcantly diﬀerentially expressed proteins. (a) Proteomics reveals 
sex-dependent protein expression diﬀerences in lung tissue. &e heatmap shows proteome data overview of 
8635 proteins with overlapping quantiﬁcation in all 4 weeks of age lung samples using hierarchical clustering. 
Columns and rows represent lung samples and proteins, respectively. &e samples are labels as sex_genotype_
ID. &e major factor for clustering is sex, and not genotype. (b) Boxplot of the three signiﬁcantly diﬀerentially 
expressed proteins. &e y-axis shows the ratios to the pool. For each gene, the ratios to the pool in the wild type 
group (WT) and knock-out group (KO) are plotted in the boxplot, respectively.
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Products) and sonicated six times for 5 sec at 200 W (Bioruptor, diagenode). Tissue lysates were incubated for one 
hour at 4 °C with rotation, and centrifuged at 21’100 g for 20 min at 4 °C. Protein concentration was measured 
with the BCA protein detection kit (&ermo Fisher Scientiﬁc). Lung lysates were denatured in sample buﬀer (Life 
Technologies) and proteins were separated on a 4–12% BisTris polyacrylamide gel (Novex by Life Technologies). 
Proteins were transferred to an Immobilon-P PVDF membrane (Millipore) using the XCell II™ Blot Module 
(Novex by LifeTechnologies). &e membrane was blocked with 5% skimmed milk in TBS 0.1% Tween and incu-
bated with rabbit anti-Pald1 (1:1000; Atlas Antibodies, HPA017343) or goat anti-actin (1:1000, Santa Cruz, 
sc-1615) antibodies overnight at 4 °C. Membranes were washed in TBS 0.1% Tween and incubated with horse-
radish peroxidase (HRP) conjugated secondary anti-rabbit (1:10’000, GE Healthcare) and anti-goat antibodies 
(1:10’000, Invitrogen), respectively. Membranes were washed in TBS 0.1% Tween and developed using ECL prime 
(GE Healthcare). Luminescence signal was detected by the ChemiDoc MP system (BioRad).
???????????????????? ????????????????????????????????????? Lungs were inﬂated and ﬁxed intratra-
cheally with 4% PFA. &e trachea was tied under pressure, and the lung was ﬁxed for 2 h in 4% PFA at 4 °C. For 
histochemical analysis, paraﬃn sections of ﬁxed lungs were dehydrated gradually in a series of 70% ethanol to 
xylene and soaked in paraﬃn (for 6 h in total) prior to embedding. Paraﬃn sections (6 µm) were deparaﬃnized 
using xylene, rehydrated in graded alcohol series (99.6% to 70% ethanol) and rinsed in distilled water. For H&E 
staining, sections were immersed sequentially in hematoxylin and eosin solutions (Histolab). Stained sections 
were dehydrated (70% ethanol to 99.6% ethanol, xylene) and mounted in PERTEX mounting media (Histolab). 
Interalveolar septal wall distance was measured by the mean linear intercept (MLI). Images from H&E stained 
lung sections were acquired on a Nikon light microscope (Nikon Eclipse 80i, Nikon digital camera DXM 1200) at 
a 400x magniﬁcation. &e MLI was obtained by dividing the length of a line drawn across the lung section by the 
total number of intercepts encountered in 10 lines per picture. Twenty-ﬁve images per section, and two sections 
per lung, were analyzed. One section was from the inferior lobe and another one from the superior lobe.
For frozen lung sections, lungs were collected and ﬁxed as described. A#er overnight incubation in 30% 
sucrose in PBS, lung sections of 5–10 µm were cut, blocked (3% BSA, 0.1% Triton x-100, 5% Normal Donkey 
serum [Jackson Immunoresearch], 5% Normal Mouse serum [Invitrogen] in PBS) and stained with rabbit 
anti-ERG (1:100, Abcam, ab92513), mouse anti-ERG (1:100, Abcam, ab140520), mouse anti-αSMA (1:100, 
Sigma, C6198), rabbit anti-prosurfactant Protein C (1:100, Abcam, ab40879), mouse anti-cytokeratin (1:100, 
Sigma, P2871), rat anti-CD68 (1:100, AbD serotec, MCA1957), rabbit anti-cleaved caspase 3 Ab-5 (1:3000, 
Neomarkers, RB-1611-P1), and mouse anti-ki67 (1:100, Dako, M7240) in combination with appropriate 
ﬂuorophore-coupled secondary antibodies. Images were obtained with the Zeiss LSM700 confocal microscope, 
63x objective and analyzed by ImageJ. For x-gal staining, frozen lung sections were post-ﬁxed in 0.2% PFA for 
10 min on ice, rinsed in PBS with 2 mM MgCl2 and permeabilized in detergent rinse (2 mM MgCl2, 0.01% sodium 
deoxycholate, 0.02% Nonidet P-40, PBS) for 10 min on ice, prior to overnight staining at 37 °C with 1 mg/ml x-gal 
(Promega) diluted in staining solution (detergent rinse containing 5 mM potassium ferricyanide, 5 mM potas-
sium ferrocyanide). Sections were washed twice for 10 min in detergent rinse, followed by PBS.
Statistical analysis of data sets of two groups was done by Student’s t-test and of three or more groups by 
one-way ANOVA using GraphPad Prism6.
???????????????????????? Lung function analysis were performed as previously reported36. Brieﬂy, lung 
function was assessed by a forced maneuver system and a Fine-Pointe RC system (Buxco Research Systems; 
Wilmington, NC, USA).
Statistical analyses were performed using R-scripts (version 3.0.2, Foundation of Statistical Computing, 
Vienna, Austria) implemented in the database (MausDB). Diﬀerences between genotypes were evaluated by 
Wilcoxon test. Statistical signiﬁcance was assumed at p < 0.05. Data are presented as median values ± interquar-
tile range.
Proteome analysis. Mouse lung samples were lysed by SDS and prepared for mass spectrometry analysis 
using a modiﬁed version of the FASP protocol29. Peptides were labelled with TMT10plex reagent according to 
the manufacturer’s protocol (&ermo Scientiﬁc) and separated by immobilized pH gradient - isoelectric focusing 
(IPG-IEF) on 3–10 strips as described previously29. Extracted peptide fractions from the IPG-IEF were separated 
using an online 3000 RSLCnano system coupled to a &ermo Scientiﬁc Q Exactive. MSGF + Percolator in the 
Galaxy platform was used to match MS spectra to the Ensembl 82 mouse protein database37.
One of the samples in Pald1 knock-out females was excluded from further analyses because it is highly likely 
that squamous epithelium could have contaminated the sample; protein expression pattern was completely dif-
ferent from others and some proteins speciﬁc to squamous epithelial cells had been detected. &e remaining 
quantiﬁed proteomics data were processed in R so#ware. To identify diﬀerentially expressed genes between dif-
ferent groups (knock-out group versus controls, male versus female), student’s t test was used and multiple test 
correction was implemented using the false discovery rate method38. Heatmap analysis was performed using 
the pheatmap packages in R so#ware. &e genes were clustered using Pearson correlation distance and the sam-
ples were clustered using Euclidean distance. &e average linkage cluster method was used to build the cluster 
dendrogram.
Data Availability. Mass spectrometry proteomics data is deposited to jPOSTrepo39 with the dataset identiﬁer 
JPST000225 & PXD005625.
All other data generated or analyzed during this study are included in this published article (and its 
Supplementary Information ﬁles).
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SUPPLEMENTARY MATERIALS & METHODS 
Auditory Brainstem response 
Auditory Brainstem Response (ABR) measurements were performed using a RP2.1 
workstation (Tucker-Davis Technologies, TDT, USA) as previously described1. In 
short, animals were anaesthetized and electrodes were placed on the vertex 
(reference) and ventrolateral to the ears (active and ground) of the animals. ABR 
potentials, as responses to broadband clicks or pure-tone frequencies, were recorded. 
Frequencies ranged from 6 to 30 kHz with a 6 kHz stepping, and sound pressure 
levels ranged from 0 to 85 dB with 5 dB steps. Hearing thresholds were determined 
for each frequency as the lowest SPL producing a measurable ABR pattern response. 
Number of mice analyzed per genotype: at 12 weeks of age 7-8 male and 7 
female mice, at 15 weeks of age 4-5 male and 5 female mice and at 18 weeks of age 
10 male and 10 female mice. For statistical analysis, a Wilcoxon Rank Sum test is 
used to analyze the thresholds of the different auditory stimuli. 
 
Genomic cdh23 analysis 
For genomic cdh23 analysis a 547 bp area spanning exon7-intron7 boundary of 
cdh23 was amplified (primers: TGTGTGTCTCCCAAGGATCA;  
AAAGCCTGCAGCATTAGGAA) using DNA isolated from Pald1+/+ and Pald1-/- 
tail biopsies and sequenced by Sanger Sequencing at the Uppsala Genome Center 
(sequencing primers: CCTCTGTCTACATTGGCCAAC; 
ATGACTCAGCAACACGGATG.   
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Analysis of PDGFRα
+
 cells 
Pald1
+/- mice bred with PDGFRαEGFP mice2 to generate Pald1+/+ : PDGFRαEGFP/+ 
mice or Pald1-/-:PDGFRαEGFP/+ offspring. The number of EGFP+ cells was 
quantified in relation to the total number of Hoechst positive cells in mages that 
were obtained with the Zeiss LSM700 confocal microscope, 63x objective and 
analyzed by ImageJ. 
 
Western blot analysis 
Snap frozen lungs from 4-week old mice were lysed in 4% (w/v) SDS, 25 mM 
HEPES pH 7.6 and 1mM DTT in ultrapure water. Tissues were disrupted with 
Tissue Tearor Homogenizer (Biospec Products) and heated at 95 °C for 5 min on a 
pre-warmed block. They were centrifuged for 30 minutes at maximum speed at 4 °C 
after sonication with Bioruptor (Diagenode, Belgium) so that supernatant could be 
used for western blot analysis. Lung lysates were denatured in sample buffer (Life 
Technologies) and proteins were separated on a 4-12 % BisTris polyacrylamide gel 
(Novex by Life Technologies). Proteins were transferred to an Immobilon-P PVDF 
membrane (Millipore) using the XCell II™ Blot Module (Novex by 
LifeTechnologies). The membrane was blocked with 5 % skimmed milk in TBS 0.1 
% Tween and incubated with rabbit anti-Hpgd (1:1000; abcam, EPR14332-19) or 
mouse anti-αTubulin (1:500, Sigma, T9026) antibodies overnight at 4°C. 
Membranes were washed in TBS 0.1 % Tween and incubated with horseradish 
peroxidase (HRP) conjugated secondary anti-rabbit (1:5,000, GE Healthcare) or 
anti-mouse antibodies (1:5,000, Invitrogen), respectively. Membranes were washed 
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in TBS 0.1 % Tween and developed using ECL prime (GE Healthcare). 
Luminescence signal was detected by the ChemiDoc MP system (BioRad).  
!
 
 57
! &!
SUPPLEMENTARY TABLES AND FIGURES 
 
Table S1: Overview of tests performed by the German Mouse Clinic and summary of 
results.  
  
Figure S1: Altered auditory responses in Pald1 mutant mice is likely due to variations in 
Cdh23. (a-b) Auditory Brainstem response (ABR) indicates increased hearing sensitivity in 
Pald1
 mutant and pure background 129SvEv mice compared to Pald1+/+ and pure background 
C57Bl/6 mice. Mean ABR thresholds SPL (Sound pressure level) for Pald1+/+ and Pald1-/- 
mice at 12 (n = 14-15 mice per genotype), 15 (n = 9-10 mice per genotype; significantly 
decreased SPL for 12-30kHz) and 18 weeks (n = 20 mice per genotype; significantly 
decreased SPL for 24-30kHz) of age (a) or for 12-week old Pald1+/+, Pald1+/- and Pald1-/- 
mice as well as pure background control C57Bl/6 and 129SvEv mice (b) is given for the 
indicated frequencies from 6 kHz to 30 kHz. Note overlapping ABR profiles between 
Pald1
+/+ and C57Bl/6, and between Pald1+/-, Pald1-/- and 129SvEv mice. Error bars: IQR. ** 
p ≤ 0.01, *** p ≤ 0.001 
(c) Genomic analysis of the Cdh23 exon 7-intron boundary demonstrated the presence of 
Cdh23
753A variant in Pald1+/+ and pure background C57BL/6JBomTac mice. In contrast, a 
heterozygous or homozygous Cdh23753G allele was present in Pald1-/- mice, which were 
generated on the 129SvEv background, and in the pure background 129SvEv control mice. 
Sequencing was performed on both DNA strands, only forward strand is shown.  
Expression of Cdh23753A leads to in-frame skipping of exon 7 and consequently results in 
reduced stability of cadherin 23 and hearing loss3. Pald1 is within 0.6 Mb of cdh23 on 
chromosome 10 and Pald1-/- mice still express the stable Cdh23753G derived from 129SvEv 
mouse strain. Therefore, it is likely that the differences in hearing sensitivity observed in 
Pald1 mutant mice are due to different Cdh23 variants and not related to the specific loss of 
paladin expression.  
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Figure S2: Paladin expression in male lungs. LacZ reporter activity (blue) is detected in 
male Pald1LacZ/LacZ mice 4 weeks and 19 weeks after birth. LacZ is broadly expressed in the 
lung tissue, except for the bronchial epithelium, which shows no reporter activity (arrow). 
Scale bar = 50 µm 
  
Figure S3: Paladin is expressed both in the epithelial and mesenchymal compartment of 
the postnatal lung (P5 and 19 weeks of age). Combined X-gal and immunofluorescence 
staining of Pald1LacZ/LacZ mice at P5 and 19 weeks (a - e) show Pald1 LacZ expression in the 
vasculature, i.e. endothelial cells in capillaries (a) but to a lesser extent in endothelial cells of 
larger blood vessels (b) as indicated by Erg staining (endothelial cell nuclei, green). In large 
blood vessels LacZ expression can be detected in vascular smooth muscle cells (c), α-smooth 
muscle actin, red). Paladin LacZ reporter is not active in pneumocytes type II at P5 but is 
active at 19 weeks (d, SPC, green), but is present in type I/II cells (e, cytokeratin, red). Scale 
bar = 20 µm. 
 
Figure S4: PDGFRα positive cells in the lung (4 -10 weeks of age). Quantification of the 
relative proportion of PDGFRα-EGFP positive cells with (n=2 at 4 weeks and n=1 at 10 
weeks) shows no differences between wild type and Pald1 knock-out lungs as compared to 
total number of cells. 
 
Figure S5: Examples of combined immunofluorescence staining for Erg and cleaved 
caspase-3 or Ki-67 in wild type female mice lung at P5.  A small proportion of endothelial 
cells (Erg, red) are also positive for cleaved caspase-3 (green) or cell cycle marker Ki-67 
(green). Scale bar = 20µm.  
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Figure S6: Hpgd protein levels in the lung. Western blot for Hpgd in both wild type and 
knock-out lungs was performed at 4 weeks after birth. a-Tubulin was used as a loading 
control. All samples were derived at the same time and divided into two parts for different 
secondary detection reagents. 
 
Figure S7: Volcano plot of the statistics result of Pald1 proteomics data. The X-axis 
shows the log2 scaled fold change between the Pald1 knockout and control, and Y-axis shows 
the –log10 scaled p values of the two group comparison. Three proteins showed statistics 
significant (false discovery rate < 0.05): Pald1, Mycbp2 and Hpgd. 
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3. Noben-Trauth, K., Zheng, Q.Y. & Johnson, K.R. Association of cadherin 
23 with polygenic inheritance and genetic modification of sensorineural 
hearing loss. Nat Genet 35, 21-23 (2003). 
!
 60
Table S1  
Overview of tests performed by the German Mouse Clinic and summary of results:   
Screen Tests Phenotype summary Pald1
-/-
 mice 
Dysmorphology, 
Bone and 
Cartilage 
Morphological observation, 
Clickbox test, DXA, X-Ray 
None 
Behavior 
 
Pre-pulse Inhibition / Acoustic 
Startle Reflex 
Increased Acoustic Startle Reflex in male 
mutant mice 
Open Field 
Small increase in center entry latency in 
mutant mice 
Neurology 
  
Auditory Brainstem Response 
Decreased sound pressure levels, related to 
Cdh23
753G
 genotype from 129SvEv mouse 
strain due to proximity to Pald1 locus (0,6 Mb) 
and not Pald1 genotype  
Grip Strength, Rotarod, Modified 
SHIRPA, Lactate 
None 
Eye Screen 
Optical Coherence Tomography 
Irregular/waved like pattern of the fundic 
blood vessels 
Eye size, Scheimpflug, Virtual 
Drum, Eye Morphology 
None 
Nociception Hotplate None 
Metabolic Screen 
Minispec and Indirect 
Calorimetry (TSE) 
None 
Clinical Chemistry 
and Hematology 
Clinical Chemistry (ad lib. fed 
mice), Hematology, IpGTT 
IpGTT: slightly increased blood glucose 
concentration 30-120 min after intraperitoneal 
glucose injection; small changes of unclear 
relevance in plasma composition in male 
mutant mice 
Immunology 
Screen 
Flow Cytometry None 
Allergy Screen 
IgE levels None 
Transepidermal water loss None 
Steroid Screen Steroid levels None 
Cardiovascular 
Screen 
Awake Echocardiography, 
Awake Electrocardiography 
Shorter QT, QTc and ST interval duration 
mainly in male mutant mice 
Lung Function 
Screen 
Lung Function 
Emphysema-like phenotype in female mutant 
mice 
Pathology Screen Macroscopy, Microscopy 
Differences in heart weight of females of 
unclear relevance 
 
Abbreviations: DXA - Dual-energy X-ray Absorptiometry; SHIRPA - SmithKline Beecham, Harwell, Imperial College, 
Royal London Hospital, phenotype assessment; IpGTT - Intraperitoneal Glucose Tolerance Test;  
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